-
1
-
-
79956142378
-
The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
-
PID: 21514250
-
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.
-
(2011)
Alzheimers Dement.
, vol.7
, Issue.3
, pp. 263-269
-
-
McKhann, G.M.1
Knopman, D.S.2
Chertkow, H.3
Hyman, B.T.4
Jack, C.R.5
Kawas, C.H.6
-
2
-
-
84922797115
-
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease
-
PID: 24795085
-
Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement. 2015;11(1):58–69.
-
(2015)
Alzheimers Dement.
, vol.11
, Issue.1
, pp. 58-69
-
-
Blennow, K.1
Dubois, B.2
Fagan, A.M.3
Lewczuk, P.4
de Leon, M.J.5
Hampel, H.6
-
3
-
-
84963632368
-
CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis
-
COI: 1:CAS:528:DC%2BC28XlslCitb8%3D, PID: 27068280
-
Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–84.
-
(2016)
Lancet Neurol
, vol.15
, Issue.7
, pp. 673-684
-
-
Olsson, B.1
Lautner, R.2
Andreasson, U.3
Ohrfelt, A.4
Portelius, E.5
Bjerke, M.6
-
4
-
-
84876147147
-
Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson’s disease?
-
COI: 1:CAS:528:DC%2BC3sXnsVajurg%3D, PID: 23450518
-
Duncan GW, Firbank MJ, O’Brien JT, Burn DJ. Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson’s disease? Mov Disord. 2013;28(4):425–38.
-
(2013)
Mov Disord
, vol.28
, Issue.4
, pp. 425-438
-
-
Duncan, G.W.1
Firbank, M.J.2
O’Brien, J.T.3
Burn, D.J.4
-
5
-
-
0033290524
-
The role of MRI in dementia
-
COI: 1:STN:280:DC%2BD3cvgsVCmsg%3D%3D, PID: 10662960
-
Pantano P, Caramia F, Pierallini A. The role of MRI in dementia. Ital J Neurol Sci. 1999;20(5 Suppl):S250–3.
-
(1999)
Ital J Neurol Sci
, vol.20
, pp. S250-S253
-
-
Pantano, P.1
Caramia, F.2
Pierallini, A.3
-
6
-
-
84906794973
-
Diffusion tensor imaging of white matter degeneration in Alzheimer’s disease and mild cognitive impairment
-
Amlien IK, Fjell AM. Diffusion tensor imaging of white matter degeneration in Alzheimer’s disease and mild cognitive impairment. Neuroscience. 2014;12(276):206–15.
-
(2014)
Neuroscience
, vol.12
, Issue.276
, pp. 206-215
-
-
Amlien, I.K.1
Fjell, A.M.2
-
7
-
-
3042770430
-
1H-MRS evaluation of metabolism in Alzheimer’s disease and vascular dementia
-
COI: 1:CAS:528:DC%2BD2cXmtl2gtL4%3D, PID: 15265265
-
Jones RS, Waldman AD. 1H-MRS evaluation of metabolism in Alzheimer’s disease and vascular dementia. Neurol Res. 2004;26(5):488–95.
-
(2004)
Neurol Res
, vol.26
, Issue.5
, pp. 488-495
-
-
Jones, R.S.1
Waldman, A.D.2
-
8
-
-
79960727510
-
Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC3MXotlygsLc%3D, PID: 21460439
-
Ewers M, Cheng X, Zhong Z, Nural HF, Walsh C, Meindl T, et al. Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer’s disease. J Alzheimers Dis. 2011;25(2):373–81.
-
(2011)
J Alzheimers Dis
, vol.25
, Issue.2
, pp. 373-381
-
-
Ewers, M.1
Cheng, X.2
Zhong, Z.3
Nural, H.F.4
Walsh, C.5
Meindl, T.6
-
9
-
-
84860215480
-
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature
-
PID: 22487856
-
Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362–81.
-
(2012)
J Neuropathol Exp Neurol
, vol.71
, Issue.5
, pp. 362-381
-
-
Nelson, P.T.1
Alafuzoff, I.2
Bigio, E.H.3
Bouras, C.4
Braak, H.5
Cairns, N.J.6
-
10
-
-
84856002055
-
National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease
-
PID: 22265587
-
Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8(1):1–13.
-
(2012)
Alzheimers Dement.
, vol.8
, Issue.1
, pp. 1-13
-
-
Hyman, B.T.1
Phelps, C.H.2
Beach, T.G.3
Bigio, E.H.4
Cairns, N.J.5
Carrillo, M.C.6
-
11
-
-
84857030932
-
National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach
-
COI: 1:CAS:528:DC%2BC38Xkt1eqtQ%3D%3D, PID: 22101365
-
Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 2012;123(1):1–11.
-
(2012)
Acta Neuropathol
, vol.123
, Issue.1
, pp. 1-11
-
-
Montine, T.J.1
Phelps, C.H.2
Beach, T.G.3
Bigio, E.H.4
Cairns, N.J.5
Dickson, D.W.6
-
12
-
-
84858046578
-
Neuropathological alterations in Alzheimer disease
-
PID: 22229116
-
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189.
-
(2011)
Cold Spring Harb Perspect Med.
, vol.1
, Issue.1
, pp. a006189
-
-
Serrano-Pozo, A.1
Frosch, M.P.2
Masliah, E.3
Hyman, B.T.4
-
13
-
-
84929094945
-
Clearance of beta-amyloid in the brain
-
COI: 1:CAS:528:DC%2BC2cXhvVGgtL3E, PID: 25312211
-
Ueno M, Chiba Y, Matsumoto K, Nakagawa T, Miyanaka H. Clearance of beta-amyloid in the brain. Curr Med Chem. 2014;21(35):4085–90.
-
(2014)
Curr Med Chem
, vol.21
, Issue.35
, pp. 4085-4090
-
-
Ueno, M.1
Chiba, Y.2
Matsumoto, K.3
Nakagawa, T.4
Miyanaka, H.5
-
14
-
-
0033202045
-
Overlap between pathology of Alzheimer disease and vascular dementia
-
PID: 10609690
-
Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(Suppl 3):S115–23.
-
(1999)
Alzheimer Dis Assoc Disord.
, vol.13
, pp. S115-S123
-
-
Kalaria, R.N.1
Ballard, C.2
-
15
-
-
84926312823
-
Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis
-
COI: 1:CAS:528:DC%2BC2MXhtlSktbc%3D, PID: 25604547
-
Viola KL, Klein WL. Amyloid beta oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129(2):183–206.
-
(2015)
Acta Neuropathol
, vol.129
, Issue.2
, pp. 183-206
-
-
Viola, K.L.1
Klein, W.L.2
-
16
-
-
0029006492
-
Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer’s disease and in frontal lobe degeneration
-
COI: 1:STN:280:DyaK28%2FmtFensA%3D%3D, PID: 7583681
-
Brun A, Liu X, Erikson C. Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer’s disease and in frontal lobe degeneration. Neurodegeneration. 1995;4(2):171–7.
-
(1995)
Neurodegeneration.
, vol.4
, Issue.2
, pp. 171-177
-
-
Brun, A.1
Liu, X.2
Erikson, C.3
-
17
-
-
84921895084
-
Emerging concepts in Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC2MXptFSmu70%3D, PID: 25387055
-
Vinters HV. Emerging concepts in Alzheimer’s disease. Annu Rev Pathol. 2015;10:291–319.
-
(2015)
Annu Rev Pathol
, vol.10
, pp. 291-319
-
-
Vinters, H.V.1
-
18
-
-
84863103124
-
A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC38XhtVOrsrvM, PID: 22813736
-
Piro JR, Benjamin DI, Duerr JM, Pi Y, Gonzales C, Wood KM, et al. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer’s disease. Cell Rep. 2012;1(6):617–23.
-
(2012)
Cell Rep.
, vol.1
, Issue.6
, pp. 617-623
-
-
Piro, J.R.1
Benjamin, D.I.2
Duerr, J.M.3
Pi, Y.4
Gonzales, C.5
Wood, K.M.6
-
19
-
-
77957970155
-
Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC3cXht1Kit7%2FL, PID: 20698820
-
Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Curr Pharm Des. 2010;16(25):2766–78.
-
(2010)
Curr Pharm Des
, vol.16
, Issue.25
, pp. 2766-2778
-
-
Agostinho, P.1
Cunha, R.A.2
Oliveira, C.3
-
20
-
-
84907169998
-
Inflammasomes in neuroinflammation and changes in brain function: a focused review
-
PID: 25339862
-
Singhal G, Jaehne EJ, Corrigan F, Toben C, Baune BT. Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front Neurosci. 2014;8:315.
-
(2014)
Front Neurosci.
, vol.8
, pp. 315
-
-
Singhal, G.1
Jaehne, E.J.2
Corrigan, F.3
Toben, C.4
Baune, B.T.5
-
21
-
-
0034237388
-
Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology
-
COI: 1:CAS:528:DC%2BD3cXks1Sqs78%3D, PID: 10817926
-
Mehlhorn G, Hollborn M, Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci. 2000;18(4–5):423–31.
-
(2000)
Int J Dev Neurosci.
, vol.18
, Issue.4-5
, pp. 423-431
-
-
Mehlhorn, G.1
Hollborn, M.2
Schliebs, R.3
-
22
-
-
0035177653
-
Application of triple immunohistochemistry to characterize amyloid plaque-associated inflammation in brains with Alzheimer’s disease
-
COI: 1:STN:280:DC%2BD38%2Fhsl2ruw%3D%3D, PID: 11440311
-
Dandrea MR, Reiser PA, Gumula NA, Hertzog BM, Andrade-Gordon P. Application of triple immunohistochemistry to characterize amyloid plaque-associated inflammation in brains with Alzheimer’s disease. Biotech Histochem. 2001;76(2):97–106.
-
(2001)
Biotech Histochem
, vol.76
, Issue.2
, pp. 97-106
-
-
Dandrea, M.R.1
Reiser, P.A.2
Gumula, N.A.3
Hertzog, B.M.4
Andrade-Gordon, P.5
-
23
-
-
0036968944
-
Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway
-
COI: 1:CAS:528:DC%2BD38Xps12rtLw%3D, PID: 12505419
-
Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, et al. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis. 2002;11(2):257–74.
-
(2002)
Neurobiol Dis
, vol.11
, Issue.2
, pp. 257-274
-
-
Giovannini, M.G.1
Scali, C.2
Prosperi, C.3
Bellucci, A.4
Vannucchi, M.G.5
Rosi, S.6
-
24
-
-
84945376575
-
The interactions of obesity, inflammation and insulin resistance in breast cancer
-
PID: 26516917
-
Rose DP, Gracheck PJ, Vona-Davis L. The interactions of obesity, inflammation and insulin resistance in breast cancer. Cancers (Basel). 2015;7(4):2147–68.
-
(2015)
Cancers (Basel).
, vol.7
, Issue.4
, pp. 2147-2168
-
-
Rose, D.P.1
Gracheck, P.J.2
Vona-Davis, L.3
-
25
-
-
0142072232
-
The insulin resistance syndrome: implications for thrombosis and cardiovascular disease
-
COI: 1:CAS:528:DC%2BD3sXnsFCns7g%3D, PID: 13679655
-
Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb. 2002;32(5–6):269–73.
-
(2002)
Pathophysiol Haemost Thromb.
, vol.32
, Issue.5-6
, pp. 269-273
-
-
Juhan-Vague, I.1
Morange, P.E.2
Alessi, M.C.3
-
26
-
-
33746156977
-
Chronic inflammation: role of adipose tissue and modulation by weight loss
-
PID: 18220615
-
You T, Nicklas BJ. Chronic inflammation: role of adipose tissue and modulation by weight loss. Curr Diabetes Rev. 2006;2(1):29–37.
-
(2006)
Curr Diabetes Rev
, vol.2
, Issue.1
, pp. 29-37
-
-
You, T.1
Nicklas, B.J.2
-
27
-
-
49649092062
-
Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease
-
COI: 1:STN:280:DC%2BD1cvovFaktw%3D%3D, PID: 18669160
-
Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg. 2008;70(3):193–219.
-
(2008)
Verh K Acad Geneeskd Belg
, vol.70
, Issue.3
, pp. 193-219
-
-
Holvoet, P.1
-
28
-
-
79960853510
-
Vascular biology of metabolic syndrome
-
PID: 21439758
-
Vykoukal D, Davies MG. Vascular biology of metabolic syndrome. J Vasc Surg. 2011;54(3):819–31.
-
(2011)
J Vasc Surg
, vol.54
, Issue.3
, pp. 819-831
-
-
Vykoukal, D.1
Davies, M.G.2
-
29
-
-
70349581633
-
Insulin resistance and Alzheimer’s disease
-
PID: 19712582
-
de la Monte SM. Insulin resistance and Alzheimer’s disease. BMB Rep. 2009;42(8):475–81.
-
(2009)
BMB Rep.
, vol.42
, Issue.8
, pp. 475-481
-
-
de la Monte, S.M.1
-
30
-
-
30444447214
-
The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BD28Xps1WktA%3D%3D, PID: 16444902
-
Messier C, Teutenberg K. The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer’s disease. Neural Plast. 2005;12(4):311–28.
-
(2005)
Neural Plast.
, vol.12
, Issue.4
, pp. 311-328
-
-
Messier, C.1
Teutenberg, K.2
-
31
-
-
33644591150
-
Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine
-
COI: 1:CAS:528:DC%2BD2MXht1ynsLjF, PID: 16340083
-
Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J Alzheimers Dis. 2005;8(3):247–68.
-
(2005)
J Alzheimers Dis
, vol.8
, Issue.3
, pp. 247-268
-
-
Rivera, E.J.1
Goldin, A.2
Fulmer, N.3
Tavares, R.4
Wands, J.R.5
de la Monte, S.M.6
-
32
-
-
84859718265
-
Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline
-
COI: 1:CAS:528:DC%2BC38Xlt1egtbY%3D, PID: 22476197
-
Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316–38.
-
(2012)
J Clin Invest.
, vol.122
, Issue.4
, pp. 1316-1338
-
-
Talbot, K.1
Wang, H.Y.2
Kazi, H.3
Han, L.Y.4
Bakshi, K.P.5
Stucky, A.6
-
33
-
-
84921983585
-
Brain insulin resistance in Alzheimer’s disease and its potential treatment with GLP-1 analogs
-
PID: 24640977
-
Talbot K. Brain insulin resistance in Alzheimer’s disease and its potential treatment with GLP-1 analogs. Neurodegener Dis Manag. 2014;4(1):31–40.
-
(2014)
Neurodegener Dis Manag.
, vol.4
, Issue.1
, pp. 31-40
-
-
Talbot, K.1
-
34
-
-
84897954401
-
CSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early versus Late Alzheimer’s Disease
-
Lee S, Tong M, Hang S, Deochand C, de la Monte S. CSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early versus Late Alzheimer’s Disease. J Alzheimers Dis Parkinsonism. 2013;31(3):128.
-
(2013)
J Alzheimers Dis Parkinsonism.
, vol.31
, Issue.3
, pp. 128
-
-
Lee, S.1
Tong, M.2
Hang, S.3
Deochand, C.4
de la Monte, S.5
-
35
-
-
65549103889
-
Brain insulin-like growth factor and neurotrophin resistance in Parkinson’s disease and dementia with Lewy bodies: potential role of manganese neurotoxicity
-
COI: 1:CAS:528:DC%2BD1MXivVSiu7Y%3D, PID: 19276553
-
Tong M, Dong M, de la Monte SM. Brain insulin-like growth factor and neurotrophin resistance in Parkinson’s disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. J Alzheimers Dis. 2009;16(3):585–99.
-
(2009)
J Alzheimers Dis
, vol.16
, Issue.3
, pp. 585-599
-
-
Tong, M.1
Dong, M.2
de la Monte, S.M.3
-
36
-
-
84899156712
-
Inflammation-sleep interface in brain disease: TNF, insulin, orexin
-
Clark IA, Vissel B. Inflammation-sleep interface in brain disease: TNF, insulin, orexin. J Neuroinflammation. 2014;21(11):51.
-
(2014)
J Neuroinflammation.
, vol.21
, Issue.11
, pp. 51
-
-
Clark, I.A.1
Vissel, B.2
-
37
-
-
84866350782
-
Metabolic syndrome, mild cognitive impairment and Alzheimer’s disease–the emerging role of systemic low-grade inflammation and adiposity
-
COI: 1:CAS:528:DC%2BC38XhtlOnt7rO, PID: 22921944
-
Misiak B, Leszek J, Kiejna A. Metabolic syndrome, mild cognitive impairment and Alzheimer’s disease–the emerging role of systemic low-grade inflammation and adiposity. Brain Res Bull. 2012;89(3–4):144–9.
-
(2012)
Brain Res Bull
, vol.89
, Issue.3-4
, pp. 144-149
-
-
Misiak, B.1
Leszek, J.2
Kiejna, A.3
-
38
-
-
84871497865
-
Diabetes and the elderly brain: sweet memories?
-
PID: 23323191
-
Samaras K, Sachdev PS. Diabetes and the elderly brain: sweet memories? Ther Adv Endocrinol Metab. 2012;3(6):189–96.
-
(2012)
Ther Adv Endocrinol Metab.
, vol.3
, Issue.6
, pp. 189-196
-
-
Samaras, K.1
Sachdev, P.S.2
-
39
-
-
84959325839
-
Inside the diabetic brain: role of different players involved in cognitive decline
-
COI: 1:CAS:528:DC%2BC2MXitVSlu7fO, PID: 26667832
-
Gaspar JM, Baptista FI, Macedo MP, Ambrosio AF. Inside the diabetic brain: role of different players involved in cognitive decline. ACS Chem Neurosci. 2016;7(2):131–42.
-
(2016)
ACS Chem Neurosci.
, vol.7
, Issue.2
, pp. 131-142
-
-
Gaspar, J.M.1
Baptista, F.I.2
Macedo, M.P.3
Ambrosio, A.F.4
-
40
-
-
33746238205
-
Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer’s disease
-
PID: 16873964
-
de la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer’s disease. J Alzheimers Dis. 2006;9(2):167–81.
-
(2006)
J Alzheimers Dis
, vol.9
, Issue.2
, pp. 167-181
-
-
de la Monte, S.M.1
Wands, J.R.2
-
41
-
-
12344315682
-
Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons
-
COI: 1:CAS:528:DC%2BD2MXhvFCmug%3D%3D, PID: 15664689
-
Cimini A, Benedetti E, Cristiano L, Sebastiani P, D’Amico MA, D’Angelo B, et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience. 2005;130(2):325–37.
-
(2005)
Neuroscience
, vol.130
, Issue.2
, pp. 325-337
-
-
Cimini, A.1
Benedetti, E.2
Cristiano, L.3
Sebastiani, P.4
D’Amico, M.A.5
D’Angelo, B.6
-
42
-
-
59649111988
-
PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury
-
PID: 19124421
-
Collino M, Patel NS, Thiemermann C. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther Adv Cardiovasc Dis. 2008;2(3):179–97.
-
(2008)
Ther Adv Cardiovasc Dis.
, vol.2
, Issue.3
, pp. 179-197
-
-
Collino, M.1
Patel, N.S.2
Thiemermann, C.3
-
43
-
-
77955343205
-
Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity
-
COI: 1:CAS:528:DC%2BC3cXhtVejt7nE, PID: 20624891
-
Dunn SE, Bhat R, Straus DS, Sobel RA, Axtell R, Johnson A, et al. Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J Exp Med. 2010;207(8):1599–608.
-
(2010)
J Exp Med
, vol.207
, Issue.8
, pp. 1599-1608
-
-
Dunn, S.E.1
Bhat, R.2
Straus, D.S.3
Sobel, R.A.4
Axtell, R.5
Johnson, A.6
-
44
-
-
70249113348
-
A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BD1MXhtFChtrvJ, PID: 19874267
-
Kalinin S, Richardson JC, Feinstein DL. A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer’s disease. Curr Alzheimer Res. 2009;6(5):431–7.
-
(2009)
Curr Alzheimer Res
, vol.6
, Issue.5
, pp. 431-437
-
-
Kalinin, S.1
Richardson, J.C.2
Feinstein, D.L.3
-
45
-
-
84877340453
-
Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARbeta/delta-null mice
-
COI: 1:CAS:528:DC%2BC3sXptV2gtLg%3D, PID: 23507144
-
Barroso E, del Valle J, Porquet D, Vieira Santos AM, Salvado L, Rodriguez-Rodriguez R, et al. Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARbeta/delta-null mice. Biochim Biophys Acta. 2013;1832(8):1241–8.
-
(2013)
Biochim Biophys Acta
, vol.1832
, Issue.8
, pp. 1241-1248
-
-
Barroso, E.1
del Valle, J.2
Porquet, D.3
Vieira Santos, A.M.4
Salvado, L.5
Rodriguez-Rodriguez, R.6
-
46
-
-
33748755428
-
Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer’s disease
-
PID: 16988486
-
de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer’s disease. J Alzheimers Dis. 2006;10(1):89–109.
-
(2006)
J Alzheimers Dis
, vol.10
, Issue.1
, pp. 89-109
-
-
de la Monte, S.M.1
Tong, M.2
Lester-Coll, N.3
Plater, M.4
Wands, J.R.5
-
47
-
-
84999114970
-
Improved brain insulin/IGF signaling and reduced neuro-inflammation with T3D–959 in an experimental model of sporadic Alzheimer’s disease
-
PID: 27802237
-
de la Monte SM, Tong M, Schiano I, Didsbury J. Improved brain insulin/IGF signaling and reduced neuro-inflammation with T3D–959 in an experimental model of sporadic Alzheimer’s disease. J Alzheimers Dis. 2017;55(2):849–64.
-
(2017)
J Alzheimers Dis.
, vol.55
, Issue.2
, pp. 849-864
-
-
de la Monte, S.M.1
Tong, M.2
Schiano, I.3
Didsbury, J.4
-
48
-
-
84924863685
-
Activation of the nuclear receptor PPARdelta is neuroprotective in a transgenic mouse model of Alzheimer’s disease through inhibition of inflammation
-
Malm T, Mariani M, Donovan LJ, Neilson L, Landreth GE. Activation of the nuclear receptor PPARdelta is neuroprotective in a transgenic mouse model of Alzheimer’s disease through inhibition of inflammation. J Neuroinflamm. 2015;12:7.
-
(2015)
J Neuroinflamm.
, vol.12
, pp. 7
-
-
Malm, T.1
Mariani, M.2
Donovan, L.J.3
Neilson, L.4
Landreth, G.E.5
-
49
-
-
84886872345
-
The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it’s time for reconciliation
-
COI: 1:CAS:528:DC%2BC2cXjtlaktw%3D%3D, PID: 24095978
-
Barone E, Di Domenico F, Mancuso C, Butterfield DA. The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it’s time for reconciliation. Neurobiol Dis. 2014;62:144–59.
-
(2014)
Neurobiol Dis
, vol.62
, pp. 144-159
-
-
Barone, E.1
Di Domenico, F.2
Mancuso, C.3
Butterfield, D.A.4
-
50
-
-
84865407887
-
Oxidative damage to RNA in aging and neurodegenerative disorders
-
COI: 1:CAS:528:DC%2BC38Xht1ais7nP, PID: 22669748
-
Nunomura A, Moreira PI, Castellani RJ, Lee HG, Zhu X, Smith MA, et al. Oxidative damage to RNA in aging and neurodegenerative disorders. Neurotox Res. 2012;22(3):231–48.
-
(2012)
Neurotox Res
, vol.22
, Issue.3
, pp. 231-248
-
-
Nunomura, A.1
Moreira, P.I.2
Castellani, R.J.3
Lee, H.G.4
Zhu, X.5
Smith, M.A.6
-
51
-
-
0034923434
-
Oxidative damage is the earliest event in Alzheimer disease
-
COI: 1:CAS:528:DC%2BD3MXmtVGmsr0%3D, PID: 11487050
-
Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60(8):759–67.
-
(2001)
J Neuropathol Exp Neurol
, vol.60
, Issue.8
, pp. 759-767
-
-
Nunomura, A.1
Perry, G.2
Aliev, G.3
Hirai, K.4
Takeda, A.5
Balraj, E.K.6
-
52
-
-
84899679810
-
Neuronal failure in Alzheimer’s disease: a view through the oxidative stress looking-glass
-
COI: 1:CAS:528:DC%2BC2cXmvFGgtr0%3D, PID: 24733654
-
Bonda DJ, Wang X, Lee HG, Smith MA, Perry G, Zhu X. Neuronal failure in Alzheimer’s disease: a view through the oxidative stress looking-glass. Neurosci Bull. 2014;30(2):243–52.
-
(2014)
Neurosci Bull.
, vol.30
, Issue.2
, pp. 243-252
-
-
Bonda, D.J.1
Wang, X.2
Lee, H.G.3
Smith, M.A.4
Perry, G.5
Zhu, X.6
-
53
-
-
0033903441
-
Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer’s disease
-
PID: 10950123
-
de la Monte SM, Luong T, Neely TR, Robinson D, Wands JR. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer’s disease. Lab Invest. 2000;80(8):1323–35.
-
(2000)
Lab Invest
, vol.80
, Issue.8
, pp. 1323-1335
-
-
de la Monte, S.M.1
Luong, T.2
Neely, T.R.3
Robinson, D.4
Wands, J.R.5
-
54
-
-
84897954482
-
Brain metabolic dysfunction at the core of Alzheimer’s disease
-
PID: 24380887
-
de la Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer’s disease. Biochem Pharmacol. 2014;88(4):548–59.
-
(2014)
Biochem Pharmacol
, vol.88
, Issue.4
, pp. 548-559
-
-
de la Monte, S.M.1
Tong, M.2
-
55
-
-
0029433282
-
Free radical damage, iron, and Alzheimer’s disease
-
PID: 8847550
-
Smith MA, Perry G. Free radical damage, iron, and Alzheimer’s disease. J Neurol Sci. 1995;134(Suppl):92–4.
-
(1995)
J Neurol Sci
, vol.134
, pp. 92-94
-
-
Smith, M.A.1
Perry, G.2
-
56
-
-
0036970184
-
Iron: a pathological mediator of Alzheimer disease?
-
COI: 1:CAS:528:DC%2BD38Xot1Ois78%3D, PID: 12401957
-
Bishop GM, Robinson SR, Liu Q, Perry G, Atwood CS, Smith MA. Iron: a pathological mediator of Alzheimer disease? Dev Neurosci. 2002;24(2–3):184–7.
-
(2002)
Dev Neurosci
, vol.24
, Issue.2-3
, pp. 184-187
-
-
Bishop, G.M.1
Robinson, S.R.2
Liu, Q.3
Perry, G.4
Atwood, C.S.5
Smith, M.A.6
-
57
-
-
65649154118
-
Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene
-
COI: 1:CAS:528:DC%2BD1MXlsFyksro%3D, PID: 19519778
-
Barbeito AG, Garringer HJ, Baraibar MA, Gao X, Arredondo M, Nunez MT, et al. Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene. J Neurochem. 2009;109(4):1067–78.
-
(2009)
J Neurochem
, vol.109
, Issue.4
, pp. 1067-1078
-
-
Barbeito, A.G.1
Garringer, H.J.2
Baraibar, M.A.3
Gao, X.4
Arredondo, M.5
Nunez, M.T.6
-
58
-
-
0028828433
-
Evidence for oxidative stress in Pick disease and corticobasal degeneration
-
COI: 1:CAS:528:DyaK2MXovVyhu7s%3D, PID: 8574681
-
Castellani R, Smith MA, Richey PL, Kalaria R, Gambetti P, Perry G. Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res. 1995;696(1–2):268–71.
-
(1995)
Brain Res
, vol.696
, Issue.1-2
, pp. 268-271
-
-
Castellani, R.1
Smith, M.A.2
Richey, P.L.3
Kalaria, R.4
Gambetti, P.5
Perry, G.6
-
59
-
-
0037144187
-
Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer’s brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants
-
COI: 1:CAS:528:DC%2BD38XmvVaisr4%3D, PID: 12231224
-
Fawcett JR, Bordayo EZ, Jackson K, Liu H, Peterson J, Svitak A, et al. Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer’s brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants. Brain Res. 2002;950(1–2):10–20.
-
(2002)
Brain Res
, vol.950
, Issue.1-2
, pp. 10-20
-
-
Fawcett, J.R.1
Bordayo, E.Z.2
Jackson, K.3
Liu, H.4
Peterson, J.5
Svitak, A.6
-
60
-
-
84943365537
-
Alpha7 nicotinic receptor activation protects against oxidative stress via heme-oxygenase I induction
-
COI: 1:CAS:528:DC%2BC2MXht1Chsb7N, PID: 26212551
-
Navarro E, Buendia I, Parada E, Leon R, Jansen-Duerr P, Pircher H, et al. Alpha7 nicotinic receptor activation protects against oxidative stress via heme-oxygenase I induction. Biochem Pharmacol. 2015;97(4):473–81.
-
(2015)
Biochem Pharmacol
, vol.97
, Issue.4
, pp. 473-481
-
-
Navarro, E.1
Buendia, I.2
Parada, E.3
Leon, R.4
Jansen-Duerr, P.5
Pircher, H.6
-
61
-
-
84874768493
-
Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1alpha, and phosphorylates GSK3beta in P301L tau transgenic mice
-
COI: 1:CAS:528:DC%2BC38Xns1eqtbs%3D, PID: 22547371
-
Fine JM, Baillargeon AM, Renner DB, Hoerster NS, Tokarev J, Colton S, et al. Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1alpha, and phosphorylates GSK3beta in P301L tau transgenic mice. Exp Brain Res. 2012;219(3):381–90.
-
(2012)
Exp Brain Res
, vol.219
, Issue.3
, pp. 381-390
-
-
Fine, J.M.1
Baillargeon, A.M.2
Renner, D.B.3
Hoerster, N.S.4
Tokarev, J.5
Colton, S.6
-
62
-
-
84869089589
-
Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice
-
COI: 1:CAS:528:DC%2BC38XptVGjtro%3D, PID: 25786865
-
Hanson LR, Fine JM, Renner DB, Svitak AL, Burns RB, Nguyen TM, et al. Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice. Drug Deliv Transl Res. 2012;2(3):160–8.
-
(2012)
Drug Deliv Transl Res.
, vol.2
, Issue.3
, pp. 160-168
-
-
Hanson, L.R.1
Fine, J.M.2
Renner, D.B.3
Svitak, A.L.4
Burns, R.B.5
Nguyen, T.M.6
-
63
-
-
84910623451
-
Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation
-
Fine JM, Renner DB, Forsberg AC, Cameron RA, Galick BT, Le C, et al. Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation. Neurosci Lett. 2015;1(584):362–7.
-
(2015)
Neurosci Lett
, vol.1
, Issue.584
, pp. 362-367
-
-
Fine, J.M.1
Renner, D.B.2
Forsberg, A.C.3
Cameron, R.A.4
Galick, B.T.5
Le, C.6
-
64
-
-
79953088080
-
si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder
-
PID: 21443795
-
de la Monte SM, Tong M, Bowling N, Moskal P. si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder. Mol Brain. 2011;4:13.
-
(2011)
Mol Brain.
, vol.4
, pp. 13
-
-
de la Monte, S.M.1
Tong, M.2
Bowling, N.3
Moskal, P.4
-
65
-
-
79961033321
-
The link between iron, metabolic syndrome, and Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC3MXjsFyqsbw%3D, PID: 20556444
-
Grunblatt E, Bartl J, Riederer P. The link between iron, metabolic syndrome, and Alzheimer’s disease. J Neural Transm (Vienna). 2011;118(3):371–9.
-
(2011)
J Neural Transm (Vienna).
, vol.118
, Issue.3
, pp. 371-379
-
-
Grunblatt, E.1
Bartl, J.2
Riederer, P.3
-
66
-
-
0029032632
-
Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain
-
COI: 1:STN:280:DyaK2M3pslOluw%3D%3D, PID: 7778849
-
Schipper HM, Cisse S, Stopa EG. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann Neurol. 1995;37(6):758–68.
-
(1995)
Ann Neurol.
, vol.37
, Issue.6
, pp. 758-768
-
-
Schipper, H.M.1
Cisse, S.2
Stopa, E.G.3
-
67
-
-
84867489401
-
HO-1/BVR-a system analysis in plasma from probable Alzheimer’s disease and mild cognitive impairment subjects: a potential biochemical marker for the prediction of the disease
-
PID: 22776971
-
Di Domenico F, Barone E, Mancuso C, Perluigi M, Cocciolo A, Mecocci P, et al. HO-1/BVR-a system analysis in plasma from probable Alzheimer’s disease and mild cognitive impairment subjects: a potential biochemical marker for the prediction of the disease. J Alzheimers Dis. 2012;32(2):277–89.
-
(2012)
J Alzheimers Dis
, vol.32
, Issue.2
, pp. 277-289
-
-
Di Domenico, F.1
Barone, E.2
Mancuso, C.3
Perluigi, M.4
Cocciolo, A.5
Mecocci, P.6
-
68
-
-
84924678620
-
Insulin resistance in Alzheimer disease: is heme oxygenase-1 an Achille’s heel?
-
COI: 1:CAS:528:DC%2BC2MXjs1yiurk%3D, PID: 25731746
-
Barone E, Butterfield DA. Insulin resistance in Alzheimer disease: is heme oxygenase-1 an Achille’s heel? Neurobiol Dis. 2015;84:69–77.
-
(2015)
Neurobiol Dis
, vol.84
, pp. 69-77
-
-
Barone, E.1
Butterfield, D.A.2
-
69
-
-
84861601576
-
Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment
-
COI: 1:CAS:528:DC%2BC38XosFCitbs%3D, PID: 22549002
-
Barone E, Di Domenico F, Sultana R, Coccia R, Mancuso C, Perluigi M, et al. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med. 2012;52(11–12):2292–301.
-
(2012)
Free Radic Biol Med.
, vol.52
, Issue.11-12
, pp. 2292-2301
-
-
Barone, E.1
Di Domenico, F.2
Sultana, R.3
Coccia, R.4
Mancuso, C.5
Perluigi, M.6
-
70
-
-
79955492902
-
HFE gene variants affect iron in the brain
-
COI: 1:CAS:528:DC%2BC3MXjvFantb8%3D, PID: 21346098
-
Nandar W, Connor JR. HFE gene variants affect iron in the brain. J Nutr. 2011;141(4):729S–39S.
-
(2011)
J Nutr
, vol.141
, Issue.4
, pp. 729S-739S
-
-
Nandar, W.1
Connor, J.R.2
-
71
-
-
0029086742
-
Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome
-
COI: 1:STN:280:DyaK2MvgsVamtg%3D%3D, PID: 7673967
-
Nielsen JE, Jensen LN, Krabbe K. Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J Neurol Neurosurg Psychiatry. 1995;59(3):318–21.
-
(1995)
J Neurol Neurosurg Psychiatry
, vol.59
, Issue.3
, pp. 318-321
-
-
Nielsen, J.E.1
Jensen, L.N.2
Krabbe, K.3
-
72
-
-
84861910177
-
Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC38XotFaksrg%3D, PID: 21514009
-
Giambattistelli F, Bucossi S, Salustri C, Panetta V, Mariani S, Siotto M, et al. Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer’s disease. Neurobiol Aging. 2012;33(8):1633–41.
-
(2012)
Neurobiol Aging
, vol.33
, Issue.8
, pp. 1633-1641
-
-
Giambattistelli, F.1
Bucossi, S.2
Salustri, C.3
Panetta, V.4
Mariani, S.5
Siotto, M.6
-
73
-
-
84890519899
-
Risk factors for development of dementia in a unique six-year cohort study. I. An exploratory, pilot study of involvement of the E4 allele of apolipoprotein E, mutations of the hemochromatosis-HFE gene, type 2 diabetes, and stroke
-
COI: 1:CAS:528:DC%2BC3sXhvV2iu7zI, PID: 24081379
-
Percy M, Somerville MJ, Hicks M, Garcia A, Colelli T, Wright E, et al. Risk factors for development of dementia in a unique six-year cohort study. I. An exploratory, pilot study of involvement of the E4 allele of apolipoprotein E, mutations of the hemochromatosis-HFE gene, type 2 diabetes, and stroke. J Alzheimers Dis. 2014;38(4):907–22.
-
(2014)
J Alzheimers Dis
, vol.38
, Issue.4
, pp. 907-922
-
-
Percy, M.1
Somerville, M.J.2
Hicks, M.3
Garcia, A.4
Colelli, T.5
Wright, E.6
-
74
-
-
0023769672
-
Abnormalities in estrogen, androgen, and insulin metabolism in idiopathic hemochromatosis
-
COI: 1:CAS:528:DyaL1MXlsVeq, PID: 3291683
-
Stremmel W, Niederau C, Berger M, Kley HK, Kruskemper HL, Strohmeyer G. Abnormalities in estrogen, androgen, and insulin metabolism in idiopathic hemochromatosis. Ann N Y Acad Sci. 1988;526:209–23.
-
(1988)
Ann N Y Acad Sci
, vol.526
, pp. 209-223
-
-
Stremmel, W.1
Niederau, C.2
Berger, M.3
Kley, H.K.4
Kruskemper, H.L.5
Strohmeyer, G.6
-
75
-
-
84863003149
-
Changes in brain transcripts related to Alzheimer’s disease in a model of HFE hemochromatosis are not consistent with increased Alzheimer’s disease risk
-
PID: 22466002
-
Johnstone DM, Graham RM, Trinder D, Riveros C, Olynyk JK, Scott RJ, et al. Changes in brain transcripts related to Alzheimer’s disease in a model of HFE hemochromatosis are not consistent with increased Alzheimer’s disease risk. J Alzheimers Dis. 2012;30(4):791–803.
-
(2012)
J Alzheimers Dis
, vol.30
, Issue.4
, pp. 791-803
-
-
Johnstone, D.M.1
Graham, R.M.2
Trinder, D.3
Riveros, C.4
Olynyk, J.K.5
Scott, R.J.6
-
76
-
-
33751104718
-
HFE mutations and Alzheimer’s disease
-
PID: 17119292
-
Connor JR, Lee SY. HFE mutations and Alzheimer’s disease. J Alzheimers Dis. 2006;10(2–3):267–76.
-
(2006)
J Alzheimers Dis
, vol.10
, Issue.2-3
, pp. 267-276
-
-
Connor, J.R.1
Lee, S.Y.2
-
77
-
-
38349131338
-
Iron genes, iron load and risk of Alzheimer’s disease
-
COI: 1:STN:280:DC%2BD28nhsVWlsg%3D%3D, PID: 17047092
-
Lehmann DJ, Worwood M, Ellis R, Wimhurst VL, Merryweather-Clarke AT, Warden DR, et al. Iron genes, iron load and risk of Alzheimer’s disease. J Med Genet. 2006;43(10):e52.
-
(2006)
J Med Genet
, vol.43
, Issue.10
-
-
Lehmann, D.J.1
Worwood, M.2
Ellis, R.3
Wimhurst, V.L.4
Merryweather-Clarke, A.T.5
Warden, D.R.6
-
78
-
-
84861752996
-
Association between HFE polymorphisms and susceptibility to Alzheimer’s disease: a meta-analysis of 22 studies including 4,365 cases and 8,652 controls
-
COI: 1:CAS:528:DC%2BC38XhvVWlsbs%3D, PID: 21701828
-
Lin M, Zhao L, Fan J, Lian XG, Ye JX, Wu L, et al. Association between HFE polymorphisms and susceptibility to Alzheimer’s disease: a meta-analysis of 22 studies including 4,365 cases and 8,652 controls. Mol Biol Rep. 2012;39(3):3089–95.
-
(2012)
Mol Biol Rep
, vol.39
, Issue.3
, pp. 3089-3095
-
-
Lin, M.1
Zhao, L.2
Fan, J.3
Lian, X.G.4
Ye, J.X.5
Wu, L.6
-
79
-
-
77956218282
-
Mitochondrial iron metabolism and its role in neurodegeneration
-
PID: 20463401
-
Horowitz MP, Greenamyre JT. Mitochondrial iron metabolism and its role in neurodegeneration. J Alzheimers Dis. 2010;20(Suppl 2):S551–68.
-
(2010)
J Alzheimers Dis
, vol.20
, pp. S551-S568
-
-
Horowitz, M.P.1
Greenamyre, J.T.2
-
80
-
-
84944911043
-
Mitochondrial iron and energetic dysfunction distinguish fibroblasts and induced neurons from pantothenate kinase-associated neurodegeneration patients
-
COI: 1:CAS:528:DC%2BC2MXlvVSlurc%3D, PID: 25836419
-
Santambrogio P, Dusi S, Guaraldo M, Rotundo LI, Broccoli V, Garavaglia B, et al. Mitochondrial iron and energetic dysfunction distinguish fibroblasts and induced neurons from pantothenate kinase-associated neurodegeneration patients. Neurobiol Dis. 2015;81:144–53.
-
(2015)
Neurobiol Dis
, vol.81
, pp. 144-153
-
-
Santambrogio, P.1
Dusi, S.2
Guaraldo, M.3
Rotundo, L.I.4
Broccoli, V.5
Garavaglia, B.6
-
81
-
-
84891835067
-
Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation
-
COI: 1:CAS:528:DC%2BC3sXhvFOlsbvM, PID: 24360804
-
Dusi S, Valletta L, Haack TB, Tsuchiya Y, Venco P, Pasqualato S, et al. Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. Am J Hum Genet. 2014;94(1):11–22.
-
(2014)
Am J Hum Genet
, vol.94
, Issue.1
, pp. 11-22
-
-
Dusi, S.1
Valletta, L.2
Haack, T.B.3
Tsuchiya, Y.4
Venco, P.5
Pasqualato, S.6
-
82
-
-
33745713669
-
Different pathophysiological mechanisms of intramitochondrial iron accumulation in acquired and congenital sideroblastic anemia caused by mitochondrial DNA deletion
-
COI: 1:CAS:528:DC%2BD28XovFWrt7o%3D, PID: 16856911
-
Matthes T, Rustin P, Trachsel H, Darbellay R, Costaridou S, Xaidara A, et al. Different pathophysiological mechanisms of intramitochondrial iron accumulation in acquired and congenital sideroblastic anemia caused by mitochondrial DNA deletion. Eur J Haematol. 2006;77(2):169–74.
-
(2006)
Eur J Haematol
, vol.77
, Issue.2
, pp. 169-174
-
-
Matthes, T.1
Rustin, P.2
Trachsel, H.3
Darbellay, R.4
Costaridou, S.5
Xaidara, A.6
-
83
-
-
77749326636
-
Mitochondrial dynamics in Alzheimer’s disease: opportunities for future treatment strategies
-
COI: 1:CAS:528:DC%2BC3cXls1SksLs%3D, PID: 20210366
-
Bonda DJ, Wang X, Perry G, Smith MA, Zhu X. Mitochondrial dynamics in Alzheimer’s disease: opportunities for future treatment strategies. Drugs Aging. 2010;27(3):181–92.
-
(2010)
Drugs Aging
, vol.27
, Issue.3
, pp. 181-192
-
-
Bonda, D.J.1
Wang, X.2
Perry, G.3
Smith, M.A.4
Zhu, X.5
-
84
-
-
0036970672
-
Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture
-
COI: 1:CAS:528:DC%2BD38Xot1Oisrg%3D, PID: 12401952
-
Sangchot P, Sharma S, Chetsawang B, Porter J, Govitrapong P, Ebadi M. Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture. Dev Neurosci. 2002;24(2–3):143–53.
-
(2002)
Dev Neurosci
, vol.24
, Issue.2-3
, pp. 143-153
-
-
Sangchot, P.1
Sharma, S.2
Chetsawang, B.3
Porter, J.4
Govitrapong, P.5
Ebadi, M.6
-
85
-
-
84871420672
-
Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC38XhtFOgt73E, PID: 22886562
-
Daulatzai MA. Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer’s disease. Neurochem Res. 2012;37(12):2627–58.
-
(2012)
Neurochem Res
, vol.37
, Issue.12
, pp. 2627-2658
-
-
Daulatzai, M.A.1
-
86
-
-
84941902135
-
Biomarkers in the diagnosis and prognosis of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC28Xhtlams7vE, PID: 25424384
-
Schaffer C, Sarad N, DeCrumpe A, Goswami D, Herrmann S, Morales J, et al. Biomarkers in the diagnosis and prognosis of Alzheimer’s disease. J Lab Autom. 2015;20(5):589–600.
-
(2015)
J Lab Autom.
, vol.20
, Issue.5
, pp. 589-600
-
-
Schaffer, C.1
Sarad, N.2
DeCrumpe, A.3
Goswami, D.4
Herrmann, S.5
Morales, J.6
-
87
-
-
0020758473
-
Regional correlation of PET and CT in senile dementia of the Alzheimer type
-
PID: 6410795
-
de Leon MJ, George AE, Ferris SH, Rosenbloom S, Christman DR, Gentes CI, et al. Regional correlation of PET and CT in senile dementia of the Alzheimer type. AJNR Am J Neuroradiol. 1983;4(3):553–6.
-
(1983)
AJNR Am J Neuroradiol.
, vol.4
, Issue.3
, pp. 553-556
-
-
de Leon, M.J.1
George, A.E.2
Ferris, S.H.3
Rosenbloom, S.4
Christman, D.R.5
Gentes, C.I.6
-
88
-
-
0026133611
-
Brain imaging in dementia of the Alzheimer type
-
COI: 1:STN:280:DyaK38%2FktVKitA%3D%3D, PID: 1938155
-
Faulstich ME. Brain imaging in dementia of the Alzheimer type. Int J Neurosci. 1991;57(1–2):39–49.
-
(1991)
Int J Neurosci
, vol.57
, Issue.1-2
, pp. 39-49
-
-
Faulstich, M.E.1
-
89
-
-
84973407800
-
In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-beta load in aged APPPS1-21 mice
-
PID: 26666747
-
Waldron AM, Wintmolders C, Bottelbergs A, Kelley JB, Schmidt ME, Stroobants S, et al. In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-beta load in aged APPPS1-21 mice. Alzheimers Res Ther. 2015;7(1):76.
-
(2015)
Alzheimers Res Ther
, vol.7
, Issue.1
, pp. 76
-
-
Waldron, A.M.1
Wintmolders, C.2
Bottelbergs, A.3
Kelley, J.B.4
Schmidt, M.E.5
Stroobants, S.6
-
90
-
-
84920911585
-
Biomarkers in the diagnosis and management of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC2cXhvFeis7rP, PID: 25468144
-
Wurtman R. Biomarkers in the diagnosis and management of Alzheimer’s disease. Metabolism. 2015;64(3 Suppl 1):S47–50.
-
(2015)
Metabolism.
, vol.64
, pp. S47-S50
-
-
Wurtman, R.1
-
91
-
-
15244350991
-
Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease
-
PID: 15750214
-
de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis. 2005;7(1):45–61.
-
(2005)
J Alzheimers Dis
, vol.7
, Issue.1
, pp. 45-61
-
-
de la Monte, S.M.1
Wands, J.R.2
-
92
-
-
84055193428
-
Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer’s disease
-
PID: 22191795
-
de la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer’s disease. Drugs. 2012;72(1):49–66.
-
(2012)
Drugs.
, vol.72
, Issue.1
, pp. 49-66
-
-
de la Monte, S.M.1
-
93
-
-
0034992635
-
Increased protein glycation in cerebrospinal fluid of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BD3MXjvFSjs7s%3D, PID: 11378244
-
Shuvaev VV, Laffont I, Serot JM, Fujii J, Taniguchi N, Siest G. Increased protein glycation in cerebrospinal fluid of Alzheimer’s disease. Neurobiol Aging. 2001;22(3):397–402.
-
(2001)
Neurobiol Aging.
, vol.22
, Issue.3
, pp. 397-402
-
-
Shuvaev, V.V.1
Laffont, I.2
Serot, J.M.3
Fujii, J.4
Taniguchi, N.5
Siest, G.6
-
94
-
-
84946473585
-
Circulating biomarker panels in Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC2MXhslClur3N, PID: 25720553
-
Zafari S, Backes C, Meese E, Keller A. Circulating biomarker panels in Alzheimer’s disease. Gerontology. 2015;61(6):497–503.
-
(2015)
Gerontology.
, vol.61
, Issue.6
, pp. 497-503
-
-
Zafari, S.1
Backes, C.2
Meese, E.3
Keller, A.4
-
95
-
-
78751706599
-
Intranasal insulin as a therapeutic option in the treatment of cognitive impairments
-
COI: 1:CAS:528:DC%2BC3MXpvV2htA%3D%3D, PID: 20849944
-
Benedict C, Frey WH 2nd, Schioth HB, Schultes B, Born J, Hallschmid M. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol. 2011;46(2–3):112–5.
-
(2011)
Exp Gerontol.
, vol.46
, Issue.2-3
, pp. 112-115
-
-
Benedict, C.1
Frey, W.H.2
Schioth, H.B.3
Schultes, B.4
Born, J.5
Hallschmid, M.6
-
96
-
-
84889001107
-
Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art
-
PID: 24215447
-
de la Monte SM. Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art. Expert Opin Drug Deliv. 2013;10(12):1699–709.
-
(2013)
Expert Opin Drug Deliv
, vol.10
, Issue.12
, pp. 1699-1709
-
-
de la Monte, S.M.1
-
97
-
-
47549105901
-
Alzheimer’s disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention
-
PID: 18590347
-
Kidd PM. Alzheimer’s disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern Med Rev. 2008;13(2):85–115.
-
(2008)
Altern Med Rev.
, vol.13
, Issue.2
, pp. 85-115
-
-
Kidd, P.M.1
-
98
-
-
40349091597
-
Intranasal insulin improves cognition and modulates beta-amyloid in early AD
-
COI: 1:CAS:528:DC%2BD1cXhtFels70%3D, PID: 17942819
-
Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008;70(6):440–8.
-
(2008)
Neurology.
, vol.70
, Issue.6
, pp. 440-448
-
-
Reger, M.A.1
Watson, G.S.2
Green, P.S.3
Wilkinson, C.W.4
Baker, L.D.5
Cholerton, B.6
-
99
-
-
68949089312
-
Alzheimer’s disease is type 3 diabetes: evidence reviewed
-
PID: 19885299
-
de la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes: evidence reviewed. J Diabetes Sci Technol. 2008;2(6):1101–13.
-
(2008)
J Diabetes Sci Technol.
, vol.2
, Issue.6
, pp. 1101-1113
-
-
de la Monte, S.M.1
Wands, J.R.2
-
100
-
-
15244351255
-
Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes?
-
COI: 1:CAS:528:DC%2BD2MXhvVSrtL8%3D, PID: 15750215
-
Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes? J Alzheimers Dis. 2005;7(1):63–80.
-
(2005)
J Alzheimers Dis
, vol.7
, Issue.1
, pp. 63-80
-
-
Steen, E.1
Terry, B.M.2
Rivera, E.J.3
Cannon, J.L.4
Neely, T.R.5
Tavares, R.6
-
101
-
-
71349085957
-
Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling
-
COI: 1:CAS:528:DC%2BD1MXhsFGrsL3O, PID: 18479783
-
Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2010;31(2):224–43.
-
(2010)
Neurobiol Aging
, vol.31
, Issue.2
, pp. 224-243
-
-
Moloney, A.M.1
Griffin, R.J.2
Timmons, S.3
O’Connor, R.4
Ravid, R.5
O’Neill, C.6
-
102
-
-
84871762341
-
Leptin, mild cognitive impairment, and dementia among elderly women
-
PID: 22859388
-
Zeki Al Hazzouri A, Stone KL, Haan MN, Yaffe K. Leptin, mild cognitive impairment, and dementia among elderly women. J Gerontol A Biol Sci Med Sci. 2013;68(2):175–80.
-
(2013)
J Gerontol A Biol Sci Med Sci.
, vol.68
, Issue.2
, pp. 175-180
-
-
Zeki Al Hazzouri, A.1
Stone, K.L.2
Haan, M.N.3
Yaffe, K.4
-
103
-
-
33845577779
-
The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer’s Disease
-
COI: 1:CAS:528:DC%2BD2sXhsFantg%3D%3D, PID: 17049785
-
Cole GM, Frautschy SA. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer’s Disease. Exp Gerontol. 2007;42(1–2):10–21.
-
(2007)
Exp Gerontol.
, vol.42
, Issue.1-2
, pp. 10-21
-
-
Cole, G.M.1
Frautschy, S.A.2
-
104
-
-
84951905432
-
Novel GLP-1 (Glucagon-Like Peptide-1) analogues and insulin in the treatment for Alzheimer’s disease and other neurodegenerative diseases
-
COI: 1:CAS:528:DC%2BC2MXitVOjs7nL, PID: 26666230
-
Calsolaro V, Edison P. Novel GLP-1 (Glucagon-Like Peptide-1) analogues and insulin in the treatment for Alzheimer’s disease and other neurodegenerative diseases. CNS Drugs. 2015;29(12):1023–39.
-
(2015)
CNS Drugs.
, vol.29
, Issue.12
, pp. 1023-1039
-
-
Calsolaro, V.1
Edison, P.2
-
105
-
-
84897829368
-
The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer’s disease
-
PID: 24529525
-
Holscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer’s disease. Alzheimers Dement. 2014;10(1 Suppl):S47–54.
-
(2014)
Alzheimers Dement.
, vol.10
, pp. S47-S54
-
-
Holscher, C.1
-
106
-
-
84952933744
-
Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC28XitVCmsg%3D%3D, PID: 26351802
-
Ji C, Xue GF, Li G, Li D, Holscher C. Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease. Rev Neurosci. 2016;27(1):61–70.
-
(2016)
Rev Neurosci
, vol.27
, Issue.1
, pp. 61-70
-
-
Ji, C.1
Xue, G.F.2
Li, G.3
Li, D.4
Holscher, C.5
-
107
-
-
74249117374
-
Role of the incretin pathway in the pathogenesis of T2DM
-
PID: 19952298
-
Freeman JS. Role of the incretin pathway in the pathogenesis of T2DM. Cleve Clin J Med. 2009;76(Suppl 5):S12–9.
-
(2009)
Cleve Clin J Med.
, vol.76
, pp. S12-S19
-
-
Freeman, J.S.1
-
108
-
-
84952984418
-
Leptin applications in 2015: what have we learned about leptin and obesity?
-
COI: 1:CAS:528:DC%2BC2MXhsVeqsb3O, PID: 26313897
-
Farr OM, Gavrieli A, Mantzoros CS. Leptin applications in 2015: what have we learned about leptin and obesity? Curr Opin Endocrinol Diabetes Obes. 2015;22(5):353–9.
-
(2015)
Curr Opin Endocrinol Diabetes Obes
, vol.22
, Issue.5
, pp. 353-359
-
-
Farr, O.M.1
Gavrieli, A.2
Mantzoros, C.S.3
-
109
-
-
84973525546
-
Leptin Signalings and Leptin Resistance
-
COI: 1:CAS:528:DC%2BC28Xktl2nsLk%3D, PID: 26904854
-
Yang XN, Zhang CY, Wang B-W, Zhu SG, Zheng RM. Leptin Signalings and Leptin Resistance. Sheng Li Ke Xue Jin Zhan. 2015;46(5):327–33.
-
(2015)
Sheng Li Ke Xue Jin Zhan.
, vol.46
, Issue.5
, pp. 327-333
-
-
Yang, X.N.1
Zhang, C.Y.2
Wang, B.-W.3
Zhu, S.G.4
Zheng, R.M.5
-
110
-
-
84877099074
-
Serum neurotrophic factor levels in patients with T2DM: relationship to metabolic syndrome components
-
COI: 1:CAS:528:DC%2BC3sXhs1ags7rK, PID: 23724627
-
Civelek S, Konukoglu D, Erdenen F, Uzun H. Serum neurotrophic factor levels in patients with T2DM: relationship to metabolic syndrome components. Clin Lab. 2013;59(3–4):369–74.
-
(2013)
Clin Lab.
, vol.59
, Issue.3-4
, pp. 369-374
-
-
Civelek, S.1
Konukoglu, D.2
Erdenen, F.3
Uzun, H.4
-
111
-
-
30344471049
-
Metabolic syndrome–neurotrophic hypothesis
-
COI: 1:CAS:528:DC%2BD28XjvVGksA%3D%3D, PID: 16298496
-
Hristova M, Aloe L. Metabolic syndrome–neurotrophic hypothesis. Med Hypotheses. 2006;66(3):545–9.
-
(2006)
Med Hypotheses
, vol.66
, Issue.3
, pp. 545-549
-
-
Hristova, M.1
Aloe, L.2
-
112
-
-
84955675161
-
Insulin-like growth factor-1 deficiency and metabolic syndrome
-
Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. J Transl Med. 2016;06(14):3.
-
(2016)
J Transl Med.
, vol.6
, Issue.14
, pp. 3
-
-
Aguirre, G.A.1
De Ita, J.R.2
de la Garza, R.G.3
Castilla-Cortazar, I.4
-
113
-
-
84958832763
-
Endothelial IGF-1 receptor signalling in diabetes and insulin resistance
-
COI: 1:CAS:528:DC%2BC2MXitVSktbrE, PID: 26712712
-
Cubbon RM, Kearney MT, Wheatcroft SB. Endothelial IGF-1 receptor signalling in diabetes and insulin resistance. Trends Endocrinol Metab. 2016;27(2):96–104.
-
(2016)
Trends Endocrinol Metab
, vol.27
, Issue.2
, pp. 96-104
-
-
Cubbon, R.M.1
Kearney, M.T.2
Wheatcroft, S.B.3
-
114
-
-
0031577526
-
Brain-derived neurotrophic factor reduces blood glucose level in obese diabetic mice but not in normal mice
-
COI: 1:CAS:528:DyaK2sXmsVGktbY%3D, PID: 9299565
-
Ono M, Ichihara J, Nonomura T, Itakura Y, Taiji M, Nakayama C, et al. Brain-derived neurotrophic factor reduces blood glucose level in obese diabetic mice but not in normal mice. Biochem Biophys Res Commun. 1997;238(2):633–7.
-
(1997)
Biochem Biophys Res Commun.
, vol.238
, Issue.2
, pp. 633-637
-
-
Ono, M.1
Ichihara, J.2
Nonomura, T.3
Itakura, Y.4
Taiji, M.5
Nakayama, C.6
-
115
-
-
84859619040
-
p75 neurotrophin receptor regulates glucose homeostasis and insulin sensitivity
-
Baeza-Raja B, Li P, Le Moan N, Sachs BD, Schachtrup C, Davalos D, et al. p75 neurotrophin receptor regulates glucose homeostasis and insulin sensitivity. Proc Natl Acad Sci USA. 2015;109(15):5838–43.
-
(2015)
Proc Natl Acad Sci USA.
, vol.109
, Issue.15
, pp. 5838-5843
-
-
Baeza-Raja, B.1
Li, P.2
Le Moan, N.3
Sachs, B.D.4
Schachtrup, C.5
Davalos, D.6
-
116
-
-
84930272425
-
Hypothalamic ER stress: a bridge between leptin resistance and obesity
-
COI: 1:CAS:528:DC%2BC2MXntlWmsL4%3D, PID: 25913783
-
Ramirez S, Claret M. Hypothalamic ER stress: a bridge between leptin resistance and obesity. FEBS Lett. 2015;589(14):1678–87.
-
(2015)
FEBS Lett
, vol.589
, Issue.14
, pp. 1678-1687
-
-
Ramirez, S.1
Claret, M.2
-
117
-
-
84995511006
-
Possible integrative actions of leptin and insulin signaling in the hypothalamus targeting energy homeostasis
-
PID: 27812350
-
Thon M, Hosoi T, Ozawa K. Possible integrative actions of leptin and insulin signaling in the hypothalamus targeting energy homeostasis. Front Endocrinol (Lausanne). 2016;7:138.
-
(2016)
Front Endocrinol (Lausanne).
, vol.7
, pp. 138
-
-
Thon, M.1
Hosoi, T.2
Ozawa, K.3
-
118
-
-
77951793008
-
Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?
-
COI: 1:CAS:528:DC%2BC3cXmtFegsLc%3D, PID: 20427697
-
Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes. 2010;59(5):1117–25.
-
(2010)
Diabetes
, vol.59
, Issue.5
, pp. 1117-1125
-
-
Meier, J.J.1
Nauck, M.A.2
-
119
-
-
84964599874
-
The incretin system ABCs in obesity and diabetes—novel therapeutic strategies for weight loss and beyond
-
COI: 1:CAS:528:DC%2BC28XptVeku7o%3D, PID: 27125902
-
Joao AL, Reis F, Fernandes R. The incretin system ABCs in obesity and diabetes—novel therapeutic strategies for weight loss and beyond. Obes Rev. 2016;17(7):553–72.
-
(2016)
Obes Rev
, vol.17
, Issue.7
, pp. 553-572
-
-
Joao, A.L.1
Reis, F.2
Fernandes, R.3
-
120
-
-
67849085394
-
Epidemiological trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer’s disease, diabetes mellitus, and non-alcoholic steatohepatitis
-
PID: 19363256
-
de la Monte SM, Neusner A, Chu J, Lawton M. Epidemiological trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer’s disease, diabetes mellitus, and non-alcoholic steatohepatitis. J Alzheimers Dis. 2009;17(3):519–29.
-
(2009)
J Alzheimers Dis
, vol.17
, Issue.3
, pp. 519-529
-
-
de la Monte, S.M.1
Neusner, A.2
Chu, J.3
Lawton, M.4
-
121
-
-
84964612303
-
The risk of overweight/obesity in mid-life and late life for the development of dementia: a systematic review and meta-analysis of longitudinal studies
-
PID: 26764391
-
Pedditizi E, Peters R, Beckett N. The risk of overweight/obesity in mid-life and late life for the development of dementia: a systematic review and meta-analysis of longitudinal studies. Age Ageing. 2016;45(1):14–21.
-
(2016)
Age Ageing
, vol.45
, Issue.1
, pp. 14-21
-
-
Pedditizi, E.1
Peters, R.2
Beckett, N.3
-
122
-
-
84901581586
-
The negative effects of obesity and poor glycemic control on cognitive function: a proposed model for possible mechanisms
-
PID: 24752836
-
Alosco ML, Gunstad J. The negative effects of obesity and poor glycemic control on cognitive function: a proposed model for possible mechanisms. Curr Diab Rep. 2014;14(6):495.
-
(2014)
Curr Diab Rep.
, vol.14
, Issue.6
, pp. 495
-
-
Alosco, M.L.1
Gunstad, J.2
-
123
-
-
34247110809
-
Relation of diabetes to mild cognitive impairment
-
PID: 17420320
-
Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol. 2007;64(4):570–5.
-
(2007)
Arch Neurol
, vol.64
, Issue.4
, pp. 570-575
-
-
Luchsinger, J.A.1
Reitz, C.2
Patel, B.3
Tang, M.X.4
Manly, J.J.5
Mayeux, R.6
-
124
-
-
84861674680
-
Type 2 diabetes and ethnic disparities in cognitive impairment
-
PID: 22774307
-
Noble JM, Manly JJ, Schupf N, Tang MX, Luchsinger JA. Type 2 diabetes and ethnic disparities in cognitive impairment. Ethn Dis. 2012;22(1):38–44.
-
(2012)
Ethn Dis.
, vol.22
, Issue.1
, pp. 38-44
-
-
Noble, J.M.1
Manly, J.J.2
Schupf, N.3
Tang, M.X.4
Luchsinger, J.A.5
-
125
-
-
70450255115
-
Obesity and Alzheimer’s disease: a link between body weight and cognitive function in old age
-
PID: 19801534
-
Naderali EK, Ratcliffe SH, Dale MC. Obesity and Alzheimer’s disease: a link between body weight and cognitive function in old age. Am J Alzheimers Dis Other Demen. 2009;24(6):445–9.
-
(2009)
Am J Alzheimers Dis Other Demen.
, vol.24
, Issue.6
, pp. 445-449
-
-
Naderali, E.K.1
Ratcliffe, S.H.2
Dale, M.C.3
-
126
-
-
67649467714
-
-
Drab SR. Recognizing the rising impact of diabetes in seniors and implications for its management. Consult Pharm. 2009;24 Suppl B:5–10
-
Drab SR. Recognizing the rising impact of diabetes in seniors and implications for its management. Consult Pharm. 2009;24 Suppl B:5–10.
-
-
-
-
127
-
-
64249144009
-
(Pre)diabetes, brain aging, and cognition
-
COI: 1:CAS:528:DC%2BD1MXkvVSktrc%3D
-
Roriz-Filho JS, Sa-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves ML, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta. 2009;1792(5):432–43.
-
(2009)
Biochim Biophys Acta
, vol.1792
, Issue.5
, pp. 432-443
-
-
Roriz-Filho, J.S.1
Sa-Roriz, T.M.2
Rosset, I.3
Camozzato, A.L.4
Santos, A.C.5
Chaves, M.L.6
-
128
-
-
84867179278
-
Metabolic derangements mediate cognitive impairment and Alzheimer’s disease: role of peripheral insulin-resistance diseases
-
de la Monte SM. Metabolic derangements mediate cognitive impairment and Alzheimer’s disease: role of peripheral insulin-resistance diseases. Panminerva Med. 2012;54(3):171–8.
-
(2012)
Panminerva Med
, vol.54
, Issue.3
, pp. 171-178
-
-
de la Monte, S.M.1
-
129
-
-
84859608708
-
Modifiable factors that alter the size of the hippocampus with ageing
-
COI: 1:CAS:528:DC%2BC38Xlt1Srsbs%3D, PID: 22410582
-
Fotuhi M, Do D, Jack C. Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol. 2012;8(4):189–202.
-
(2012)
Nat Rev Neurol.
, vol.8
, Issue.4
, pp. 189-202
-
-
Fotuhi, M.1
Do, D.2
Jack, C.3
-
130
-
-
84940766574
-
Emerging links between type 2 diabetes and Alzheimer’s disease
-
PID: 26069723
-
Sridhar GR, Lakshmi G, Nagamani G. Emerging links between type 2 diabetes and Alzheimer’s disease. World J Diabetes. 2015;6(5):744–51.
-
(2015)
World J Diabetes.
, vol.6
, Issue.5
, pp. 744-751
-
-
Sridhar, G.R.1
Lakshmi, G.2
Nagamani, G.3
-
131
-
-
84896717143
-
Relationships between diabetes and cognitive impairment
-
PID: 24582101
-
de la Monte SM. Relationships between diabetes and cognitive impairment. Endocrinol Metab Clin North Am. 2014;43(1):245–67.
-
(2014)
Endocrinol Metab Clin North Am
, vol.43
, Issue.1
, pp. 245-267
-
-
de la Monte, S.M.1
-
132
-
-
84928116660
-
Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment
-
COI: 1:CAS:528:DC%2BC28XnsFelsrY%3D, PID: 25792818
-
Li X, Song D, Leng SX. Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment. Clin Interv Aging. 2015;10:549–60.
-
(2015)
Clin Interv Aging
, vol.10
, pp. 549-560
-
-
Li, X.1
Song, D.2
Leng, S.X.3
-
133
-
-
84989332872
-
Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome
-
COI: 1:CAS:528:DC%2BC2MXjvFOhtL0%3D, PID: 25766618
-
Kim B, Feldman EL. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp Mol Med. 2015;47:e149.
-
(2015)
Exp Mol Med
, vol.47
-
-
Kim, B.1
Feldman, E.L.2
-
134
-
-
81355151398
-
Insulin resistance and pathological brain ageing
-
COI: 1:CAS:528:DC%2BC38Xns12hsA%3D%3D, PID: 21974744
-
Cholerton B, Baker LD, Craft S. Insulin resistance and pathological brain ageing. Diabet Med. 2011;28(12):1463–75.
-
(2011)
Diabet Med
, vol.28
, Issue.12
, pp. 1463-1475
-
-
Cholerton, B.1
Baker, L.D.2
Craft, S.3
-
135
-
-
78650122129
-
Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer’s disease
-
PID: 20444434
-
Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, Sancarlo D, et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer’s disease. Ageing Res Rev. 2010;9(4):399–417.
-
(2010)
Ageing Res Rev.
, vol.9
, Issue.4
, pp. 399-417
-
-
Frisardi, V.1
Solfrizzi, V.2
Seripa, D.3
Capurso, C.4
Santamato, A.5
Sancarlo, D.6
-
136
-
-
4644286910
-
Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BD2cXjvVCltr8%3D, PID: 15033922
-
Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J. 2004;18(7):902–4.
-
(2004)
FASEB J.
, vol.18
, Issue.7
, pp. 902-904
-
-
Ho, L.1
Qin, W.2
Pompl, P.N.3
Xiang, Z.4
Wang, J.5
Zhao, Z.6
-
137
-
-
52449087540
-
Limited Alzheimer-type neurodegeneration in experimental obesity and T2DM
-
COI: 1:CAS:528:DC%2BD1cXhtVKmtb3O, PID: 18780965
-
Moroz N, Tong M, Longato L, Xu H, de la Monte SM. Limited Alzheimer-type neurodegeneration in experimental obesity and T2DM. J Alzheimers Dis. 2008;15(1):29–44.
-
(2008)
J Alzheimers Dis
, vol.15
, Issue.1
, pp. 29-44
-
-
Moroz, N.1
Tong, M.2
Longato, L.3
Xu, H.4
de la Monte, S.M.5
-
138
-
-
70349744089
-
Insulin resistance and neurodegeneration: roles of obesity, T2DM and non-alcoholic steatohepatitis
-
PID: 19777393
-
de la Monte SM, Longato L, Tong M, Wands JR. Insulin resistance and neurodegeneration: roles of obesity, T2DM and non-alcoholic steatohepatitis. Curr Opin Investig Drugs. 2009;10(10):1049–60.
-
(2009)
Curr Opin Investig Drugs
, vol.10
, Issue.10
, pp. 1049-1060
-
-
de la Monte, S.M.1
Longato, L.2
Tong, M.3
Wands, J.R.4
-
139
-
-
84901392386
-
Liver diseases
-
PID: 24796105
-
Nagoshi S. Liver diseases. Nihon Rinsho. 2014;72(4):726–9.
-
(2014)
Nihon Rinsho.
, vol.72
, Issue.4
, pp. 726-729
-
-
Nagoshi, S.1
-
140
-
-
67649687040
-
Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis
-
PID: 19387108
-
Lyn-Cook LE Jr, Lawton M, Tong M, Silbermann E, Longato L, Jiao P, et al. Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J Alzheimers Dis. 2009;16(4):715–29.
-
(2009)
J Alzheimers Dis
, vol.16
, Issue.4
, pp. 715-729
-
-
Lyn-Cook, L.E.1
Lawton, M.2
Tong, M.3
Silbermann, E.4
Longato, L.5
Jiao, P.6
-
141
-
-
84862817126
-
A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer’s disease in the ADNI cohort
-
PID: 22245343
-
Meda SA, Narayanan B, Liu J, Perrone-Bizzozero NI, Stevens MC, Calhoun VD, et al. A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer’s disease in the ADNI cohort. Neuroimage. 2012;60(3):1608–21.
-
(2012)
Neuroimage.
, vol.60
, Issue.3
, pp. 1608-1621
-
-
Meda, S.A.1
Narayanan, B.2
Liu, J.3
Perrone-Bizzozero, N.I.4
Stevens, M.C.5
Calhoun, V.D.6
-
142
-
-
84855181205
-
Mediterranean diet in healthy lifestyle and prevention of stroke
-
PID: 22034786
-
Demarin V, Lisak M, Morovic S. Mediterranean diet in healthy lifestyle and prevention of stroke. Acta Clin Croat. 2011;50(1):67–77.
-
(2011)
Acta Clin Croat.
, vol.50
, Issue.1
, pp. 67-77
-
-
Demarin, V.1
Lisak, M.2
Morovic, S.3
-
143
-
-
84908156476
-
Preventive benefits of natural nutrition and lifestyle counseling against Alzheimer’s disease onset
-
PID: 25238764
-
Polidori MC. Preventive benefits of natural nutrition and lifestyle counseling against Alzheimer’s disease onset. J Alzheimers Dis. 2014;42(Suppl 4):S475–82.
-
(2014)
J Alzheimers Dis
, vol.42
, pp. S475-S482
-
-
Polidori, M.C.1
-
144
-
-
84904348791
-
Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis
-
PID: 24962204
-
Beydoun MA, Beydoun HA, Gamaldo AA, Teel A, Zonderman AB, Wang Y. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health. 2014;14:643.
-
(2014)
BMC Public Health.
, vol.14
, pp. 643
-
-
Beydoun, M.A.1
Beydoun, H.A.2
Gamaldo, A.A.3
Teel, A.4
Zonderman, A.B.5
Wang, Y.6
-
145
-
-
78649427539
-
Vascular basis for brain degeneration: faltering controls and risk factors for dementia
-
PID: 21091952
-
Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev. 2010;68(Suppl 2):S74–87.
-
(2010)
Nutr Rev
, vol.68
, pp. S74-S87
-
-
Kalaria, R.N.1
-
146
-
-
79960563163
-
Bidirectional metabolic regulation of neurocognitive function
-
COI: 1:CAS:528:DC%2BC3MXhsFCqsL7I, PID: 21236352
-
Stranahan AM, Mattson MP. Bidirectional metabolic regulation of neurocognitive function. Neurobiol Learn Mem. 2011;96(4):507–16.
-
(2011)
Neurobiol Learn Mem
, vol.96
, Issue.4
, pp. 507-516
-
-
Stranahan, A.M.1
Mattson, M.P.2
-
147
-
-
84935016038
-
Olive oil phenols as promising multi-targeting agents against Alzheimer’s disease
-
PID: 26092624
-
Rigacci S. Olive oil phenols as promising multi-targeting agents against Alzheimer’s disease. Adv Exp Med Biol. 2015;863:1–20.
-
(2015)
Adv Exp Med Biol
, vol.863
, pp. 1-20
-
-
Rigacci, S.1
-
148
-
-
84953836387
-
Diabetes, glycaemia, and cognition-a secondary analysis of the Finnish Diabetes Prevention Study
-
COI: 1:CAS:528:DC%2BC28XpsFOiug%3D%3D, PID: 26172529
-
Lehtisalo J, Lindstrom J, Ngandu T, Kivipelto M, Ahtiluoto S, Ilanne-Parikka P, et al. Diabetes, glycaemia, and cognition-a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes Metab Res Rev. 2016;32(1):102–10.
-
(2016)
Diabetes Metab Res Rev.
, vol.32
, Issue.1
, pp. 102-110
-
-
Lehtisalo, J.1
Lindstrom, J.2
Ngandu, T.3
Kivipelto, M.4
Ahtiluoto, S.5
Ilanne-Parikka, P.6
-
149
-
-
84880326722
-
High-sugar diets, type 2 diabetes and Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC3sXptVOqsL0%3D, PID: 23657152
-
Moreira PI. High-sugar diets, type 2 diabetes and Alzheimer’s disease. Curr Opin Clin Nutr Metab Care. 2013;16(4):440–5.
-
(2013)
Curr Opin Clin Nutr Metab Care.
, vol.16
, Issue.4
, pp. 440-445
-
-
Moreira, P.I.1
-
150
-
-
84874629047
-
Smoking exacerbates amyloid pathology in a mouse model of Alzheimer’s disease
-
PID: 23422663
-
Moreno-Gonzalez I, Estrada LD, Sanchez-Mejias E, Soto C. Smoking exacerbates amyloid pathology in a mouse model of Alzheimer’s disease. Nat Commun. 2013;4:1495.
-
(2013)
Nat Commun.
, vol.4
, pp. 1495
-
-
Moreno-Gonzalez, I.1
Estrada, L.D.2
Sanchez-Mejias, E.3
Soto, C.4
-
151
-
-
84883453608
-
Neurotoxic saboteurs: straws that break the hippo’s (hippocampus) back drive cognitive impairment and Alzheimer’s Disease
-
COI: 1:CAS:528:DC%2BC3sXhtlGmur7E, PID: 23820984
-
Daulatzai MA. Neurotoxic saboteurs: straws that break the hippo’s (hippocampus) back drive cognitive impairment and Alzheimer’s Disease. Neurotox Res. 2013;24(3):407–59.
-
(2013)
Neurotox Res
, vol.24
, Issue.3
, pp. 407-459
-
-
Daulatzai, M.A.1
-
152
-
-
10744221613
-
DNA damage in nasal and brain tissues of canines exposed to air pollutants is associated with evidence of chronic brain inflammation and neurodegeneration
-
COI: 1:CAS:528:DC%2BD3sXmsV2huro%3D, PID: 14692621
-
Calderon-Garciduenas L, Maronpot RR, Torres-Jardon R, Henriquez-Roldan C, Schoonhoven R, Acuna-Ayala H, et al. DNA damage in nasal and brain tissues of canines exposed to air pollutants is associated with evidence of chronic brain inflammation and neurodegeneration. Toxicol Pathol. 2003;31(5):524–38.
-
(2003)
Toxicol Pathol.
, vol.31
, Issue.5
, pp. 524-538
-
-
Calderon-Garciduenas, L.1
Maronpot, R.R.2
Torres-Jardon, R.3
Henriquez-Roldan, C.4
Schoonhoven, R.5
Acuna-Ayala, H.6
-
153
-
-
8544267937
-
Brain inflammation and Alzheimer’s-like pathology in individuals exposed to severe air pollution
-
PID: 15513908
-
Calderon-Garciduenas L, Reed W, Maronpot RR, Henriquez-Roldan C, Delgado-Chavez R, Calderon-Garciduenas A, et al. Brain inflammation and Alzheimer’s-like pathology in individuals exposed to severe air pollution. Toxicol Pathol. 2004;32(6):650–8.
-
(2004)
Toxicol Pathol.
, vol.32
, Issue.6
, pp. 650-658
-
-
Calderon-Garciduenas, L.1
Reed, W.2
Maronpot, R.R.3
Henriquez-Roldan, C.4
Delgado-Chavez, R.5
Calderon-Garciduenas, A.6
-
154
-
-
84919380771
-
Type 3 diabetes is sporadic Alzheimers disease: mini-review
-
PID: 25088942
-
de la Monte SM. Type 3 diabetes is sporadic Alzheimers disease: mini-review. Eur Neuropsychopharmacol. 2014;24(12):1954–60.
-
(2014)
Eur Neuropsychopharmacol
, vol.24
, Issue.12
, pp. 1954-1960
-
-
de la Monte, S.M.1
-
155
-
-
68949161708
-
Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer’s disease
-
PID: 19542621
-
de la Monte SM, Tong M. Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer’s disease. J Alzheimers Dis. 2009;17(4):817–25.
-
(2009)
J Alzheimers Dis
, vol.17
, Issue.4
, pp. 817-825
-
-
de la Monte, S.M.1
Tong, M.2
-
156
-
-
76249083449
-
Nitrosamine exposure exacerbates high fat diet-mediated T2DM, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment
-
PID: 20034403
-
de la Monte SM, Tong M, Lawton M, Longato L. Nitrosamine exposure exacerbates high fat diet-mediated T2DM, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment. Mol Neurodegener. 2009;4:54.
-
(2009)
Mol Neurodegener.
, vol.4
, pp. 54
-
-
de la Monte, S.M.1
Tong, M.2
Lawton, M.3
Longato, L.4
-
157
-
-
68249127000
-
Nitrosamine exposure causes insulin resistance diseases: relevance to T2DM, non-alcoholic steatohepatitis, and Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BD1MXptVCht7w%3D, PID: 20387270
-
Tong M, Neusner A, Longato L, Lawton M, Wands JR, de la Monte SM. Nitrosamine exposure causes insulin resistance diseases: relevance to T2DM, non-alcoholic steatohepatitis, and Alzheimer’s disease. J Alzheimers Dis. 2009;17(4):827–44.
-
(2009)
J Alzheimers Dis
, vol.17
, Issue.4
, pp. 827-844
-
-
Tong, M.1
Neusner, A.2
Longato, L.3
Lawton, M.4
Wands, J.R.5
de la Monte, S.M.6
-
158
-
-
84959138448
-
Tobacco nitrosamines as culprits in disease: mechanisms reviewed
-
COI: 1:CAS:528:DC%2BC28XhtVartr8%3D, PID: 26767836
-
Yalcin E, de la Monte S. Tobacco nitrosamines as culprits in disease: mechanisms reviewed. J Physiol Biochem. 2016;72(1):107–20.
-
(2016)
J Physiol Biochem.
, vol.72
, Issue.1
, pp. 107-120
-
-
Yalcin, E.1
de la Monte, S.2
-
159
-
-
70350450959
-
Promising strategies for the prevention of dementia
-
PID: 19822776
-
Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol. 2009;66(10):1210–5.
-
(2009)
Arch Neurol
, vol.66
, Issue.10
, pp. 1210-1215
-
-
Middleton, L.E.1
Yaffe, K.2
-
160
-
-
4043127617
-
Pharmacotherapeutic approaches to the prevention of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BD2cXhtVKnt7rJ, PID: 15555488
-
Standridge JB. Pharmacotherapeutic approaches to the prevention of Alzheimer’s disease. Am J Geriatr Pharmacother. 2004;2(2):119–32.
-
(2004)
Am J Geriatr Pharmacother.
, vol.2
, Issue.2
, pp. 119-132
-
-
Standridge, J.B.1
-
161
-
-
65349152565
-
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
-
COI: 1:CAS:528:DC%2BD1MXitlGgtbo%3D, PID: 19225406
-
Boimel M, Grigoriadis N, Lourbopoulos A, Touloumi O, Rosenmann D, Abramsky O, et al. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J Neuropathol Exp Neurol. 2009;68(3):314–25.
-
(2009)
J Neuropathol Exp Neurol
, vol.68
, Issue.3
, pp. 314-325
-
-
Boimel, M.1
Grigoriadis, N.2
Lourbopoulos, A.3
Touloumi, O.4
Rosenmann, D.5
Abramsky, O.6
-
162
-
-
77958608578
-
Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer’s mice
-
COI: 1:CAS:528:DC%2BC3cXhtlyqtLrE, PID: 20962218
-
Piedrahita D, Hernandez I, Lopez-Tobon A, Fedorov D, Obara B, Manjunath BS, et al. Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer’s mice. J Neurosci. 2010;30(42):13966–76.
-
(2010)
J Neurosci
, vol.30
, Issue.42
, pp. 13966-13976
-
-
Piedrahita, D.1
Hernandez, I.2
Lopez-Tobon, A.3
Fedorov, D.4
Obara, B.5
Manjunath, B.S.6
-
163
-
-
77049116286
-
Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology
-
COI: 1:CAS:528:DC%2BC3cXht1SltLs%3D, PID: 20110614
-
Leroy K, Ando K, Heraud C, Yilmaz Z, Authelet M, Boeynaems JM, et al. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimers Dis. 2010;19(2):705–19.
-
(2010)
J Alzheimers Dis
, vol.19
, Issue.2
, pp. 705-719
-
-
Leroy, K.1
Ando, K.2
Heraud, C.3
Yilmaz, Z.4
Authelet, M.5
Boeynaems, J.M.6
-
164
-
-
84871717940
-
Curcuminoids and resveratrol as anti-Alzheimer agents
-
PID: 23276553
-
Villaflores OB, Chen YJ, Chen CP, Yeh JM, Wu TY. Curcuminoids and resveratrol as anti-Alzheimer agents. Taiwan J Obstet Gynecol. 2012;51(4):515–25.
-
(2012)
Taiwan J Obstet Gynecol.
, vol.51
, Issue.4
, pp. 515-525
-
-
Villaflores, O.B.1
Chen, Y.J.2
Chen, C.P.3
Yeh, J.M.4
Wu, T.Y.5
-
165
-
-
84879460570
-
Curcumin-conjugated nanoliposomes with high affinity for Abeta deposits: possible applications to Alzheimer disease
-
COI: 1:CAS:528:DC%2BC3sXisVGksbw%3D, PID: 23220328
-
Lazar AN, Mourtas S, Youssef I, Parizot C, Dauphin A, Delatour B, et al. Curcumin-conjugated nanoliposomes with high affinity for Abeta deposits: possible applications to Alzheimer disease. Nanomedicine. 2013;9(5):712–21.
-
(2013)
Nanomedicine.
, vol.9
, Issue.5
, pp. 712-721
-
-
Lazar, A.N.1
Mourtas, S.2
Youssef, I.3
Parizot, C.4
Dauphin, A.5
Delatour, B.6
-
166
-
-
77956402632
-
REVIEW: curcumin and Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC3cXht1GjtbbE, PID: 20406252
-
Hamaguchi T, Ono K, Yamada M. REVIEW: curcumin and Alzheimer’s disease. CNS Neurosci Ther. 2010;16(5):285–97.
-
(2010)
CNS Neurosci Ther
, vol.16
, Issue.5
, pp. 285-297
-
-
Hamaguchi, T.1
Ono, K.2
Yamada, M.3
-
167
-
-
84964632197
-
Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology
-
PID: 26747862
-
Olmos-Alonso A, Schetters ST, Sri S, Askew K, Mancuso R, Vargas-Caballero M, et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology. Brain. 2016;139(Pt 3):891–907.
-
(2016)
Brain.
, vol.139
, pp. 891-907
-
-
Olmos-Alonso, A.1
Schetters, S.T.2
Sri, S.3
Askew, K.4
Mancuso, R.5
Vargas-Caballero, M.6
-
168
-
-
84955179058
-
Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC28XoslyjtA%3D%3D, PID: 26652155
-
Goozee KG, Shah TM, Sohrabi HR, Rainey-Smith SR, Brown B, Verdile G, et al. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer’s disease. Br J Nutr. 2016;115(3):449–65.
-
(2016)
Br J Nutr
, vol.115
, Issue.3
, pp. 449-465
-
-
Goozee, K.G.1
Shah, T.M.2
Sohrabi, H.R.3
Rainey-Smith, S.R.4
Brown, B.5
Verdile, G.6
-
169
-
-
84906966961
-
Implicating the role of lycopene in restoration of mitochondrial enzymes and BDNF levels in beta-amyloid induced Alzheimers disease
-
Prakash A, Kumar A. Implicating the role of lycopene in restoration of mitochondrial enzymes and BDNF levels in beta-amyloid induced Alzheimers disease. Eur J Pharmacol. 2014;15(741):104–11.
-
(2014)
Eur J Pharmacol
, vol.15
, Issue.741
, pp. 104-111
-
-
Prakash, A.1
Kumar, A.2
-
170
-
-
39549119848
-
Natural antioxidants in Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BD2sXhtlGmu77I, PID: 18042001
-
Mancuso C, Bates TE, Butterfield DA, Calafato S, Cornelius C, De Lorenzo A, et al. Natural antioxidants in Alzheimer’s disease. Expert Opin Investig Drugs. 2007;16(12):1921–31.
-
(2007)
Expert Opin Investig Drugs
, vol.16
, Issue.12
, pp. 1921-1931
-
-
Mancuso, C.1
Bates, T.E.2
Butterfield, D.A.3
Calafato, S.4
Cornelius, C.5
De Lorenzo, A.6
-
171
-
-
0036084541
-
Antioxidant strategies for Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BD38XltlOru7w%3D, PID: 12133201
-
Grundman M, Grundman M, Delaney P. Antioxidant strategies for Alzheimer’s disease. Proc Nutr Soc. 2002;61(2):191–202.
-
(2002)
Proc Nutr Soc.
, vol.61
, Issue.2
, pp. 191-202
-
-
Grundman, M.1
Grundman, M.2
Delaney, P.3
-
172
-
-
0032837106
-
Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy
-
COI: 1:CAS:528:DyaK1MXmsVCjs7c%3D, PID: 10512372
-
Kishi Y, Schmelzer JD, Yao JK, Zollman PJ, Nickander KK, Tritschler HJ, et al. Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. Diabetes. 1999;48(10):2045–51.
-
(1999)
Diabetes
, vol.48
, Issue.10
, pp. 2045-2051
-
-
Kishi, Y.1
Schmelzer, J.D.2
Yao, J.K.3
Zollman, P.J.4
Nickander, K.K.5
Tritschler, H.J.6
-
173
-
-
0033080764
-
Alpha-lipoic acid provides neuroprotection from ischemia-reperfusion injury of peripheral nerve
-
COI: 1:CAS:528:DyaK1MXhvVGhsbg%3D, PID: 10223404
-
Mitsui Y, Schmelzer JD, Zollman PJ, Mitsui M, Tritschler HJ, Low PA. Alpha-lipoic acid provides neuroprotection from ischemia-reperfusion injury of peripheral nerve. J Neurol Sci. 1999;163(1):11–6.
-
(1999)
J Neurol Sci
, vol.163
, Issue.1
, pp. 11-16
-
-
Mitsui, Y.1
Schmelzer, J.D.2
Zollman, P.J.3
Mitsui, M.4
Tritschler, H.J.5
Low, P.A.6
-
174
-
-
84878786543
-
Oxidative modification of lipoic acid by HNE in Alzheimer disease brain
-
COI: 1:CAS:528:DC%2BC2cXptFOqtw%3D%3D, PID: 24024140
-
Hardas SS, Sultana R, Clark AM, Beckett TL, Szweda LI, Murphy MP, et al. Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. Redox Biol. 2013;1:80–5.
-
(2013)
Redox Biol.
, vol.1
, pp. 80-85
-
-
Hardas, S.S.1
Sultana, R.2
Clark, A.M.3
Beckett, T.L.4
Szweda, L.I.5
Murphy, M.P.6
-
175
-
-
0033958696
-
Vitamin E and Alzheimer disease: the basis for additional clinical trials
-
COI: 1:STN:280:DC%2BD3c7kt1Onsg%3D%3D, PID: 10681271
-
Grundman M. Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr. 2000;71(2):630S–6S.
-
(2000)
Am J Clin Nutr
, vol.71
, Issue.2
, pp. 630S-636S
-
-
Grundman, M.1
-
176
-
-
84872196114
-
-
Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2008(3):CD002854
-
Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2008(3):CD002854.
-
-
-
-
177
-
-
2142743810
-
Phytonutrient deficiency: the place of palm fruit
-
COI: 1:CAS:528:DC%2BD3sXpsF2itbo%3D, PID: 14506002
-
Wattanapenpaiboon N, Wahlqvist MW. Phytonutrient deficiency: the place of palm fruit. Asia Pac J Clin Nutr. 2003;12(3):363–8.
-
(2003)
Asia Pac J Clin Nutr.
, vol.12
, Issue.3
, pp. 363-368
-
-
Wattanapenpaiboon, N.1
Wahlqvist, M.W.2
-
178
-
-
0037430760
-
The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo
-
COI: 1:CAS:528:DC%2BD3sXit1Knu7Y%3D, PID: 12654342
-
Scali C, Giovannini MG, Prosperi C, Bellucci A, Pepeu G, Casamenti F. The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience. 2003;117(4):909–19.
-
(2003)
Neuroscience
, vol.117
, Issue.4
, pp. 909-919
-
-
Scali, C.1
Giovannini, M.G.2
Prosperi, C.3
Bellucci, A.4
Pepeu, G.5
Casamenti, F.6
-
179
-
-
21644444260
-
Ginkgo biloba and neurodegenerative disorders
-
Christen Y. Ginkgo biloba and neurodegenerative disorders. Front Biosci. 2004;1(9):3091–104.
-
(2004)
Front Biosci.
, vol.1
, Issue.9
, pp. 3091-3104
-
-
Christen, Y.1
-
180
-
-
30144433689
-
Role of melatonin in Alzheimer-like neurodegeneration
-
PID: 16364209
-
Wang JZ, Wang ZF. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin. 2006;27(1):41–9.
-
(2006)
Acta Pharmacol Sin
, vol.27
, Issue.1
, pp. 41-49
-
-
Wang, J.Z.1
Wang, Z.F.2
-
181
-
-
34250816837
-
Is antioxidant therapy a viable alternative for mild cognitive impairment? Examination of the evidence
-
COI: 1:CAS:528:DC%2BD2sXmvFSnu7Y%3D, PID: 17495472
-
Ancelin ML, Christen Y, Ritchie K. Is antioxidant therapy a viable alternative for mild cognitive impairment? Examination of the evidence. Dement Geriatr Cogn Disord. 2007;24(1):1–19.
-
(2007)
Dement Geriatr Cogn Disord
, vol.24
, Issue.1
, pp. 1-19
-
-
Ancelin, M.L.1
Christen, Y.2
Ritchie, K.3
-
182
-
-
55049112715
-
-
Farina N, Isaac MG, Clark AR, Rusted J, Tabet N. Vitamin E for Alzheimer’s dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2012;11:CD002854
-
Farina N, Isaac MG, Clark AR, Rusted J, Tabet N. Vitamin E for Alzheimer’s dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2012;11:CD002854.
-
-
-
-
183
-
-
84903708253
-
Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease—challenges and perspectives
-
COI: 1:CAS:528:DC%2BC2cXpt1Wnsrg%3D, PID: 24079767
-
Polidori MC, Nelles G. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease—challenges and perspectives. Curr Pharm Des. 2014;20(18):3083–92.
-
(2014)
Curr Pharm Des
, vol.20
, Issue.18
, pp. 3083-3092
-
-
Polidori, M.C.1
Nelles, G.2
-
184
-
-
84858148877
-
Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC38Xjs1GrtbY%3D, PID: 22019723
-
Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. Biochim Biophys Acta. 2012;1822(5):631–8.
-
(2012)
Biochim Biophys Acta
, vol.1822
, Issue.5
, pp. 631-638
-
-
Mecocci, P.1
Polidori, M.C.2
-
185
-
-
33748634913
-
Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer’s disease
-
PID: 16990077
-
Levey A, Lah J, Goldstein F, Steenland K, Bliwise D. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer’s disease. Clin Ther. 2006;28(7):991–1001.
-
(2006)
Clin Ther
, vol.28
, Issue.7
, pp. 991-1001
-
-
Levey, A.1
Lah, J.2
Goldstein, F.3
Steenland, K.4
Bliwise, D.5
-
186
-
-
84885456046
-
The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
-
COI: 1:CAS:528:DC%2BC3sXhsVyltb3K, PID: 24052108
-
McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013;126(4):479–97.
-
(2013)
Acta Neuropathol
, vol.126
, Issue.4
, pp. 479-497
-
-
McGeer, P.L.1
McGeer, E.G.2
-
187
-
-
0037393454
-
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report
-
COI: 1:CAS:528:DC%2BD3sXisVOmu78%3D, PID: 12640446
-
Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9(4):448–52.
-
(2003)
Nat Med
, vol.9
, Issue.4
, pp. 448-452
-
-
Nicoll, J.A.1
Wilkinson, D.2
Holmes, C.3
Steart, P.4
Markham, H.5
Weller, R.O.6
-
188
-
-
34247113214
-
Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia
-
PID: 17420322
-
Bombois S, Maurage CA, Gompel M, Deramecourt V, Mackowiak-Cordoliani MA, Black RS, et al. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol. 2007;64(4):583–7.
-
(2007)
Arch Neurol
, vol.64
, Issue.4
, pp. 583-587
-
-
Bombois, S.1
Maurage, C.A.2
Gompel, M.3
Deramecourt, V.4
Mackowiak-Cordoliani, M.A.5
Black, R.S.6
-
189
-
-
67849130968
-
Developing novel immunogens for a safe and effective Alzheimer’s disease vaccine
-
COI: 1:CAS:528:DC%2BD1MXhsVeht7rE, PID: 19660650
-
Lemere CA. Developing novel immunogens for a safe and effective Alzheimer’s disease vaccine. Prog Brain Res. 2009;175:83–93.
-
(2009)
Prog Brain Res
, vol.175
, pp. 83-93
-
-
Lemere, C.A.1
-
190
-
-
77955351154
-
Treatment strategy of Alzheimer’s disease: pause in clinical trials of Abeta vaccine and next steps
-
PID: 20675870
-
Kuzuhara S. Treatment strategy of Alzheimer’s disease: pause in clinical trials of Abeta vaccine and next steps. Brain Nerve. 2010;62(7):659–66.
-
(2010)
Brain Nerve
, vol.62
, Issue.7
, pp. 659-666
-
-
Kuzuhara, S.1
-
191
-
-
84949642187
-
Combined omega-3 fatty acids, aerobic exercise and cognitive stimulation prevents decline in gray matter volume of the frontal, parietal and cingulate cortex in patients with mild cognitive impairment
-
Kobe T, Witte AV, Schnelle A, Lesemann A, Fabian S, Tesky VA, et al. Combined omega-3 fatty acids, aerobic exercise and cognitive stimulation prevents decline in gray matter volume of the frontal, parietal and cingulate cortex in patients with mild cognitive impairment. Neuroimage. 2016;1(131):226–38.
-
(2016)
Neuroimage.
, vol.1
, Issue.131
, pp. 226-238
-
-
Kobe, T.1
Witte, A.V.2
Schnelle, A.3
Lesemann, A.4
Fabian, S.5
Tesky, V.A.6
-
192
-
-
0038711749
-
Ethanol impairs insulin-stimulated neuronal survival in the developing brain: role of PTEN phosphatase
-
COI: 1:CAS:528:DC%2BD3sXltlKqtLo%3D, PID: 12700235
-
Xu J, Yeon JE, Chang H, Tison G, Chen GJ, Wands J, et al. Ethanol impairs insulin-stimulated neuronal survival in the developing brain: role of PTEN phosphatase. J Biol Chem. 2003;278(29):26929–37.
-
(2003)
J Biol Chem
, vol.278
, Issue.29
, pp. 26929-26937
-
-
Xu, J.1
Yeon, J.E.2
Chang, H.3
Tison, G.4
Chen, G.J.5
Wands, J.6
-
193
-
-
44649198605
-
Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo
-
COI: 1:CAS:528:DC%2BD1cXnvVSqtr4%3D, PID: 18549783
-
Chiu SL, Chen CM, Cline HT. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron. 2008;58(5):708–19.
-
(2008)
Neuron
, vol.58
, Issue.5
, pp. 708-719
-
-
Chiu, S.L.1
Chen, C.M.2
Cline, H.T.3
-
194
-
-
84928793245
-
New insights into insulin: the anti-inflammatory effect and its clinical relevance
-
PID: 24765237
-
Sun Q, Li J, Gao F. New insights into insulin: the anti-inflammatory effect and its clinical relevance. World J Diabetes. 2014;5(2):89–96.
-
(2014)
World J Diabetes.
, vol.5
, Issue.2
, pp. 89-96
-
-
Sun, Q.1
Li, J.2
Gao, F.3
-
195
-
-
84911895310
-
Insulin reverses the high-fat diet-induced increase in brain Abeta and improves memory in an animal model of Alzheimer disease
-
COI: 1:CAS:528:DC%2BC2cXitVCgtr%2FN, PID: 25008180
-
Vandal M, White PJ, Tremblay C, St-Amour I, Chevrier G, Emond V, et al. Insulin reverses the high-fat diet-induced increase in brain Abeta and improves memory in an animal model of Alzheimer disease. Diabetes. 2014;63(12):4291–301.
-
(2014)
Diabetes
, vol.63
, Issue.12
, pp. 4291-4301
-
-
Vandal, M.1
White, P.J.2
Tremblay, C.3
St-Amour, I.4
Chevrier, G.5
Emond, V.6
-
196
-
-
33748478598
-
Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain
-
COI: 1:CAS:528:DC%2BD28XhtVCjt7%2FP, PID: 16909201
-
Soscia SJ, Tong M, Xu XJ, Cohen AC, Chu J, Wands JR, et al. Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain. Cell Mol Life Sci. 2006;63(17):2039–56.
-
(2006)
Cell Mol Life Sci
, vol.63
, Issue.17
, pp. 2039-2056
-
-
Soscia, S.J.1
Tong, M.2
Xu, X.J.3
Cohen, A.C.4
Chu, J.5
Wands, J.R.6
-
197
-
-
84865522894
-
Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans
-
COI: 1:CAS:528:DC%2BC38XhtlantbvI, PID: 22586589
-
Jauch-Chara K, Friedrich A, Rezmer M, Melchert UH, Scholand-Engler HG, Hallschmid M, et al. Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans. Diabetes. 2012;61(9):2261–8.
-
(2012)
Diabetes.
, vol.61
, Issue.9
, pp. 2261-2268
-
-
Jauch-Chara, K.1
Friedrich, A.2
Rezmer, M.3
Melchert, U.H.4
Scholand-Engler, H.G.5
Hallschmid, M.6
-
198
-
-
84898048515
-
Intranasal insulin increases regional cerebral blood flow in the insular cortex in men independently of cortisol manipulation
-
PID: 23907764
-
Schilling TM, Ferreira de Sa DS, Westerhausen R, Strelzyk F, Larra MF, Hallschmid M, et al. Intranasal insulin increases regional cerebral blood flow in the insular cortex in men independently of cortisol manipulation. Hum Brain Mapp. 2014;35(5):1944–56.
-
(2014)
Hum Brain Mapp
, vol.35
, Issue.5
, pp. 1944-1956
-
-
Schilling, T.M.1
Ferreira de Sa, D.S.2
Westerhausen, R.3
Strelzyk, F.4
Larra, M.F.5
Hallschmid, M.6
-
199
-
-
10944228564
-
Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer’s disease intervention
-
COI: 1:CAS:528:DC%2BD2cXhtFagurfP, PID: 15590928
-
Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer’s disease intervention. J Neurosci. 2004;24(49):11120–6.
-
(2004)
J Neurosci
, vol.24
, Issue.49
, pp. 11120-11126
-
-
Zhao, L.1
Teter, B.2
Morihara, T.3
Lim, G.P.4
Ambegaokar, S.S.5
Ubeda, O.J.6
-
200
-
-
57649134261
-
Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease
-
PID: 19091002
-
Hanson LR, Frey WH 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9(Suppl 3):S5.
-
(2008)
BMC Neurosci.
, vol.9
, pp. S5
-
-
Hanson, L.R.1
Frey, W.H.2
-
201
-
-
85021663083
-
Intranasal drug delivery bypasses the blood-brain barrier
-
Williams GS. Intranasal drug delivery bypasses the blood-brain barrier. Neurol Rev. 2016;24(4):40–1.
-
(2016)
Neurol Rev.
, vol.24
, Issue.4
, pp. 40-41
-
-
Williams, G.S.1
-
202
-
-
85047698627
-
Sniffing neuropeptides: a transnasal approach to the human brain
-
COI: 1:CAS:528:DC%2BD38XjvVygu7w%3D, PID: 11992114
-
Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci. 2002;5(6):514–6.
-
(2002)
Nat Neurosci
, vol.5
, Issue.6
, pp. 514-516
-
-
Born, J.1
Lange, T.2
Kern, W.3
McGregor, G.P.4
Bickel, U.5
Fehm, H.L.6
-
203
-
-
84880555817
-
Intranasal insulin as a treatment for Alzheimer’s disease: a review of basic research and clinical evidence
-
COI: 1:CAS:528:DC%2BC3sXhvVWmsrbL, PID: 23719722
-
Freiherr J, Hallschmid M, Frey WH 2nd, Brunner YF, Chapman CD, Holscher C, et al. Intranasal insulin as a treatment for Alzheimer’s disease: a review of basic research and clinical evidence. CNS Drugs. 2013;27(7):505–14.
-
(2013)
CNS Drugs.
, vol.27
, Issue.7
, pp. 505-514
-
-
Freiherr, J.1
Hallschmid, M.2
Frey, W.H.3
Brunner, Y.F.4
Chapman, C.D.5
Holscher, C.6
-
204
-
-
84890839540
-
Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer’s disease
-
PID: 24333407
-
Alagiakrishnan K, Sankaralingam S, Ghosh M, Mereu L, Senior P. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer’s disease. Discov Med. 2013;16(90):277–86.
-
(2013)
Discov Med.
, vol.16
, Issue.90
, pp. 277-286
-
-
Alagiakrishnan, K.1
Sankaralingam, S.2
Ghosh, M.3
Mereu, L.4
Senior, P.5
-
205
-
-
84973428782
-
Targeting insulin signaling for the treatment of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC2MXhslGksbjK, PID: 26268336
-
Chen Y, Zhang J, Zhang B, Gong CX. Targeting insulin signaling for the treatment of Alzheimer’s disease. Curr Top Med Chem. 2016;16(5):485–92.
-
(2016)
Curr Top Med Chem
, vol.16
, Issue.5
, pp. 485-492
-
-
Chen, Y.1
Zhang, J.2
Zhang, B.3
Gong, C.X.4
-
206
-
-
31844434789
-
Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype
-
COI: 1:CAS:528:DC%2BD28XhtlCms70%3D, PID: 15964100
-
Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2006;27(3):451–8.
-
(2006)
Neurobiol Aging
, vol.27
, Issue.3
, pp. 451-458
-
-
Reger, M.A.1
Watson, G.S.2
Frey, W.H.3
Baker, L.D.4
Cholerton, B.5
Keeling, M.L.6
-
207
-
-
47849123972
-
Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults
-
COI: 1:CAS:528:DC%2BD1cXkvV2rtrs%3D, PID: 18430999
-
Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis. 2008;13(3):323–31.
-
(2008)
J Alzheimers Dis
, vol.13
, Issue.3
, pp. 323-331
-
-
Reger, M.A.1
Watson, G.S.2
Green, P.S.3
Baker, L.D.4
Cholerton, B.5
Fishel, M.A.6
-
208
-
-
84922666525
-
Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia
-
COI: 1:CAS:528:DC%2BC2MXitlWrsrc%3D, PID: 25374101
-
Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia. J Alzheimers Dis. 2015;44(3):897–906.
-
(2015)
J Alzheimers Dis
, vol.44
, Issue.3
, pp. 897-906
-
-
Claxton, A.1
Baker, L.D.2
Hanson, A.3
Trittschuh, E.H.4
Cholerton, B.5
Morgan, A.6
-
209
-
-
84975749523
-
Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST(R) T1)
-
PID: 26773446
-
Hirsch IB, Franek E, Mersebach H, Bardtrum L, Hermansen K. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST(R) T1). Diabet Med. 2016. doi:10.1111/dme.13068.
-
(2016)
Diabet Med.
-
-
Hirsch, I.B.1
Franek, E.2
Mersebach, H.3
Bardtrum, L.4
Hermansen, K.5
-
210
-
-
85027931443
-
Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes
-
COI: 1:CAS:528:DC%2BC28XhtlKnurjI, PID: 26612062
-
Christiansen JS, Niskanen L, Rasmussen S, Johansen T, Fulcher G. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes. J Diabetes. 2016;8(5):720–8.
-
(2016)
J Diabetes.
, vol.8
, Issue.5
, pp. 720-728
-
-
Christiansen, J.S.1
Niskanen, L.2
Rasmussen, S.3
Johansen, T.4
Fulcher, G.5
-
211
-
-
84925433127
-
Clinical use of insulin degludec: practical experience and pragmatic suggestions
-
PID: 25838998
-
Kalra S, Gupta Y. Clinical use of insulin degludec: practical experience and pragmatic suggestions. N Am J Med Sci. 2015;7(3):81–5.
-
(2015)
N Am J Med Sci.
, vol.7
, Issue.3
, pp. 81-85
-
-
Kalra, S.1
Gupta, Y.2
-
212
-
-
33847617011
-
Mechanisms of action of glucagon-like peptide 1 in the pancreas
-
COI: 1:CAS:528:DC%2BD2sXislKjsb4%3D, PID: 17306374
-
Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007;113(3):546–93.
-
(2007)
Pharmacol Ther
, vol.113
, Issue.3
, pp. 546-593
-
-
Doyle, M.E.1
Egan, J.M.2
-
213
-
-
84874722479
-
The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC3sXjsFKrsrg%3D, PID: 23011726
-
Long-Smith CM, Manning S, McClean PL, Coakley MF, O’Halloran DJ, Holscher C, et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer’s disease. Neuromolecular Med. 2013;15(1):102–14.
-
(2013)
Neuromolecular Med.
, vol.15
, Issue.1
, pp. 102-114
-
-
Long-Smith, C.M.1
Manning, S.2
McClean, P.L.3
Coakley, M.F.4
O’Halloran, D.J.5
Holscher, C.6
-
214
-
-
77955611520
-
Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer’s disease?
-
COI: 1:CAS:528:DC%2BC3cXhtVWqu7rF, PID: 20698813
-
Irwin N, Gault V, Flatt PR. Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer’s disease? Expert Opin Investig Drugs. 2010;19(9):1039–48.
-
(2010)
Expert Opin Investig Drugs
, vol.19
, Issue.9
, pp. 1039-1048
-
-
Irwin, N.1
Gault, V.2
Flatt, P.R.3
-
215
-
-
84888203544
-
Incretin actions beyond the pancreas: lessons from knockout mice
-
COI: 1:CAS:528:DC%2BC3sXhsFOltLrP, PID: 24095602
-
Yabe D, Seino Y. Incretin actions beyond the pancreas: lessons from knockout mice. Curr Opin Pharmacol. 2013;13(6):946–53.
-
(2013)
Curr Opin Pharmacol
, vol.13
, Issue.6
, pp. 946-953
-
-
Yabe, D.1
Seino, Y.2
-
216
-
-
0028867442
-
Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites
-
COI: 1:STN:280:DyaK287kvFKnsg%3D%3D, PID: 8563978
-
Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci. 1995;7(11):2294–300.
-
(1995)
Eur J Neurosci
, vol.7
, Issue.11
, pp. 2294-2300
-
-
Goke, R.1
Larsen, P.J.2
Mikkelsen, J.D.3
Sheikh, S.P.4
-
217
-
-
0033545166
-
Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system
-
COI: 1:CAS:528:DyaK1MXhtlWntw%3D%3D, PID: 9886047
-
Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol. 1999;403(2):261–80.
-
(1999)
J Comp Neurol.
, vol.403
, Issue.2
, pp. 261-280
-
-
Merchenthaler, I.1
Lane, M.2
Shughrue, P.3
-
218
-
-
84897883235
-
Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model
-
COI: 1:CAS:528:DC%2BC2cXls1Ois7c%3D, PID: 24296712
-
Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S, et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes. 2014;63(4):1224–33.
-
(2014)
Diabetes
, vol.63
, Issue.4
, pp. 1224-1233
-
-
Richards, P.1
Parker, H.E.2
Adriaenssens, A.E.3
Hodgson, J.M.4
Cork, S.C.5
Trapp, S.6
-
219
-
-
84856102513
-
GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake
-
COI: 1:CAS:528:DC%2BC38XitVegsbo%3D, PID: 22128031
-
Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology. 2012;153(2):647–58.
-
(2012)
Endocrinology
, vol.153
, Issue.2
, pp. 647-658
-
-
Alhadeff, A.L.1
Rupprecht, L.E.2
Hayes, M.R.3
-
220
-
-
0029859220
-
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
-
COI: 1:CAS:528:DyaK28Xms1OitLc%3D, PID: 8897973
-
Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271(4 Pt 2):R848–56.
-
(1996)
Am J Physiol
, vol.271
, Issue.4
, pp. R848-R856
-
-
Tang-Christensen, M.1
Larsen, P.J.2
Goke, R.3
Fink-Jensen, A.4
Jessop, D.S.5
Moller, M.6
-
221
-
-
13344282056
-
A role for glucagon-like peptide-1 in the central regulation of feeding
-
COI: 1:CAS:528:DyaK28XivVKgsA%3D%3D, PID: 8538742
-
Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379(6560):69–72.
-
(1996)
Nature
, vol.379
, Issue.6560
, pp. 69-72
-
-
Turton, M.D.1
O’Shea, D.2
Gunn, I.3
Beak, S.A.4
Edwards, C.M.5
Meeran, K.6
-
222
-
-
0037349072
-
Entry of exendin-4 into brain is rapid but may be limited at high doses
-
COI: 1:CAS:528:DC%2BD3sXhslKqsbY%3D, PID: 12629557
-
Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord. 2003;27(3):313–8.
-
(2003)
Int J Obes Relat Metab Disord
, vol.27
, Issue.3
, pp. 313-318
-
-
Kastin, A.J.1
Akerstrom, V.2
-
223
-
-
79960741385
-
Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4
-
COI: 1:CAS:528:DC%2BC3MXhtVemt7bF, PID: 21693680
-
Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology. 2011;152(8):3103–12.
-
(2011)
Endocrinology
, vol.152
, Issue.8
, pp. 3103-3112
-
-
Kanoski, S.E.1
Fortin, S.M.2
Arnold, M.3
Grill, H.J.4
Hayes, M.R.5
-
224
-
-
80052074914
-
A physiological role of glucagon-like peptide-1 receptors in the central nervous system of Suncus murinus (house musk shrew)
-
COI: 1:CAS:528:DC%2BC3MXhtV2it7%2FN, PID: 21756894
-
Chan SW, Lin G, Yew DT, Rudd JA. A physiological role of glucagon-like peptide-1 receptors in the central nervous system of Suncus murinus (house musk shrew). Eur J Pharmacol. 2011;668(1–2):340–6.
-
(2011)
Eur J Pharmacol
, vol.668
, Issue.1-2
, pp. 340-346
-
-
Chan, S.W.1
Lin, G.2
Yew, D.T.3
Rudd, J.A.4
-
225
-
-
84933046243
-
Central nervous system regulation of intestinal lipoprotein metabolism by glucagon-like peptide-1 via a brain-gut axis
-
COI: 1:CAS:528:DC%2BC2MXntVWnsr0%3D, PID: 25675997
-
Farr S, Baker C, Naples M, Taher J, Iqbal J, Hussain M, et al. Central nervous system regulation of intestinal lipoprotein metabolism by glucagon-like peptide-1 via a brain-gut axis. Arterioscler Thromb Vasc Biol. 2015;35(5):1092–100.
-
(2015)
Arterioscler Thromb Vasc Biol
, vol.35
, Issue.5
, pp. 1092-1100
-
-
Farr, S.1
Baker, C.2
Naples, M.3
Taher, J.4
Iqbal, J.5
Hussain, M.6
-
226
-
-
78650507366
-
GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons
-
COI: 1:CAS:528:DC%2BC3cXhsF2rtrzE, PID: 20736238
-
Griffioen KJ, Wan R, Okun E, Wang X, Lovett-Barr MR, Li Y, et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res. 2011;89(1):72–8.
-
(2011)
Cardiovasc Res
, vol.89
, Issue.1
, pp. 72-78
-
-
Griffioen, K.J.1
Wan, R.2
Okun, E.3
Wang, X.4
Lovett-Barr, M.R.5
Li, Y.6
-
227
-
-
84892579498
-
Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice
-
COI: 1:CAS:528:DC%2BC3sXhsV2gtLrF, PID: 22892942
-
Rachmany L, Tweedie D, Li Y, Rubovitch V, Holloway HW, Miller J, et al. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr). 2013;35(5):1621–36.
-
(2013)
Age (Dordr).
, vol.35
, Issue.5
, pp. 1621-1636
-
-
Rachmany, L.1
Tweedie, D.2
Li, Y.3
Rubovitch, V.4
Holloway, H.W.5
Miller, J.6
-
228
-
-
84869234340
-
The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s disease
-
Duffy AM, Holscher C. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s disease. Neuroscience. 2013;3(228):294–300.
-
(2013)
Neuroscience
, vol.3
, Issue.228
, pp. 294-300
-
-
Duffy, A.M.1
Holscher, C.2
-
229
-
-
84916604386
-
Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer’s disease?
-
PID: 25418147
-
Garcia-Casares N, Garcia-Arnes JA, Gomez-Huelgas R, Valdivielso-Felices P, Garcia-Arias C, Gonzalez-Santos P. Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer’s disease? Rev Neurol. 2014;59(11):517–24.
-
(2014)
Rev Neurol.
, vol.59
, Issue.11
, pp. 517-524
-
-
Garcia-Casares, N.1
Garcia-Arnes, J.A.2
Gomez-Huelgas, R.3
Valdivielso-Felices, P.4
Garcia-Arias, C.5
Gonzalez-Santos, P.6
-
230
-
-
84929504903
-
Drugs developed for treatment of diabetes show protective effects in Alzheimer’s and Parkinson’s diseases
-
PID: 25331995
-
Holscher C. Drugs developed for treatment of diabetes show protective effects in Alzheimer’s and Parkinson’s diseases. Sheng Li Xue Bao. 2014;66(5):497–510.
-
(2014)
Sheng Li Xue Bao.
, vol.66
, Issue.5
, pp. 497-510
-
-
Holscher, C.1
-
231
-
-
84896920228
-
Insulin, incretins and other growth factors as potential novel treatments for Alzheimer’s and Parkinson’s diseases
-
PID: 24646283
-
Holscher C. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer’s and Parkinson’s diseases. Biochem Soc Trans. 2014;42(2):593–9.
-
(2014)
Biochem Soc Trans
, vol.42
, Issue.2
, pp. 593-599
-
-
Holscher, C.1
-
232
-
-
85008506589
-
New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders
-
PID: 26557956
-
Irwin N, Flatt PR. New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders. World J Diabetes. 2015;6(15):1285–95.
-
(2015)
World J Diabetes.
, vol.6
, Issue.15
, pp. 1285-1295
-
-
Irwin, N.1
Flatt, P.R.2
-
233
-
-
84931562584
-
DPP-4 inhibitor linagliptin attenuates abeta-induced cytotoxicity through activation of AMPK in neuronal cells
-
COI: 1:CAS:528:DC%2BC2MXhtVGmsbjI, PID: 26010513
-
Kornelius E, Lin CL, Chang HH, Li HH, Huang WN, Yang YS, et al. DPP-4 inhibitor linagliptin attenuates abeta-induced cytotoxicity through activation of AMPK in neuronal cells. CNS Neurosci Ther. 2015;21(7):549–57.
-
(2015)
CNS Neurosci Ther
, vol.21
, Issue.7
, pp. 549-557
-
-
Kornelius, E.1
Lin, C.L.2
Chang, H.H.3
Li, H.H.4
Huang, W.N.5
Yang, Y.S.6
-
234
-
-
84974559551
-
In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled. Double-blind clinical trial
-
PID: 27252647
-
Gejl M, Gjedde A, Egefjord L, Moller A, Hansen SB, Vang K, et al. In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled. Double-blind clinical trial. Front Aging Neurosci. 2016;8:108.
-
(2016)
Front Aging Neurosci.
, vol.8
, pp. 108
-
-
Gejl, M.1
Gjedde, A.2
Egefjord, L.3
Moller, A.4
Hansen, S.B.5
Vang, K.6
-
235
-
-
84901280798
-
Sulphonylurea usage in melioidosis is associated with severe disease and suppressed immune response
-
PID: 24762472
-
Liu X, Foo G, Lim WP, Ravikumar S, Sim SH, Win MS, et al. Sulphonylurea usage in melioidosis is associated with severe disease and suppressed immune response. PLoS Negl Trop Dis. 2014;8(4):e2795.
-
(2014)
PLoS Negl Trop Dis.
, vol.8
, Issue.4
-
-
Liu, X.1
Foo, G.2
Lim, W.P.3
Ravikumar, S.4
Sim, S.H.5
Win, M.S.6
-
236
-
-
84890094663
-
Increased risk of cognitive impairment in patients with diabetes is associated with metformin
-
COI: 1:CAS:528:DC%2BC3sXhs1ylt7jP, PID: 24009301
-
Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care. 2013;36(10):2981–7.
-
(2013)
Diabetes Care
, vol.36
, Issue.10
, pp. 2981-2987
-
-
Moore, E.M.1
Mander, A.G.2
Ames, D.3
Kotowicz, M.A.4
Carne, R.P.5
Brodaty, H.6
-
237
-
-
84881567755
-
Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy
-
COI: 1:CAS:528:DC%2BC3sXht1GjsrfJ, PID: 23797633
-
Wheeler S, Moore K, Forsberg CW, Riley K, Floyd JS, Smith NL, et al. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia. 2013;56(9):1934–43.
-
(2013)
Diabetologia
, vol.56
, Issue.9
, pp. 1934-1943
-
-
Wheeler, S.1
Moore, K.2
Forsberg, C.W.3
Riley, K.4
Floyd, J.S.5
Smith, N.L.6
-
238
-
-
84902239478
-
Long-term metformin usage and cognitive function among older adults with diabetes
-
COI: 1:CAS:528:DC%2BC2cXptVCgu7Y%3D, PID: 24577463
-
Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis. 2014;41(1):61–8.
-
(2014)
J Alzheimers Dis
, vol.41
, Issue.1
, pp. 61-68
-
-
Ng, T.P.1
Feng, L.2
Yap, K.B.3
Lee, T.S.4
Tan, C.H.5
Winblad, B.6
-
239
-
-
84961773449
-
Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial
-
COI: 1:CAS:528:DC%2BC28XksFCjtbY%3D, PID: 26890736
-
Luchsinger JA, Perez T, Chang H, Mehta P, Steffener J, Pradabhan G, et al. Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial. J Alzheimers Dis. 2016;51(2):501–14.
-
(2016)
J Alzheimers Dis
, vol.51
, Issue.2
, pp. 501-514
-
-
Luchsinger, J.A.1
Perez, T.2
Chang, H.3
Mehta, P.4
Steffener, J.5
Pradabhan, G.6
-
240
-
-
0033395836
-
The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways
-
COI: 1:CAS:528:DC%2BD3cXksVOjtw%3D%3D, PID: 10548883, (discussion 67–8)
-
Kliewer SA, Lehmann JM, Milburn MV, Willson TM. The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog Horm Res. 1999;54:345–67 (discussion 67–8).
-
(1999)
Recent Prog Horm Res.
, vol.54
, pp. 345-367
-
-
Kliewer, S.A.1
Lehmann, J.M.2
Milburn, M.V.3
Willson, T.M.4
-
242
-
-
77953493182
-
Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages
-
Fuentes L, Roszer T, Ricote M. Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages. Mediat Inflamm. 2010;2010:219583.
-
(2010)
Mediat Inflamm
, vol.2010
, pp. 219583
-
-
Fuentes, L.1
Roszer, T.2
Ricote, M.3
-
243
-
-
0042405041
-
Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle
-
COI: 1:CAS:528:DC%2BD3sXmt1Crt7k%3D, PID: 12864748
-
Gilde AJ, Van Bilsen M. Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle. Acta Physiol Scand. 2003;178(4):425–34.
-
(2003)
Acta Physiol Scand
, vol.178
, Issue.4
, pp. 425-434
-
-
Gilde, A.J.1
Van Bilsen, M.2
-
244
-
-
0037900979
-
Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors
-
COI: 1:CAS:528:DC%2BD3sXktFehtL4%3D, PID: 12746275
-
Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 2003;144(6):2201–7.
-
(2003)
Endocrinology
, vol.144
, Issue.6
, pp. 2201-2207
-
-
Lee, C.H.1
Olson, P.2
Evans, R.M.3
-
245
-
-
0030602866
-
The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation
-
COI: 1:STN:280:DyaK28zhtlygsA%3D%3D, PID: 8695669
-
Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta. 1996;1302(2):93–109.
-
(1996)
Biochim Biophys Acta
, vol.1302
, Issue.2
, pp. 93-109
-
-
Schoonjans, K.1
Staels, B.2
Auwerx, J.3
-
246
-
-
33644592598
-
Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study
-
PID: 16286438
-
Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005;13(11):950–8.
-
(2005)
Am J Geriatr Psychiatry.
, vol.13
, Issue.11
, pp. 950-958
-
-
Watson, G.S.1
Cholerton, B.A.2
Reger, M.A.3
Baker, L.D.4
Plymate, S.R.5
Asthana, S.6
-
247
-
-
77958173794
-
Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment
-
COI: 1:CAS:528:DC%2BC3cXhtFahs7jM, PID: 20435794
-
Abbatecola AM, Lattanzio F, Molinari AM, Cioffi M, Mansi L, Rambaldi P, et al. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care. 2010;33(8):1706–11.
-
(2010)
Diabetes Care
, vol.33
, Issue.8
, pp. 1706-1711
-
-
Abbatecola, A.M.1
Lattanzio, F.2
Molinari, A.M.3
Cioffi, M.4
Mansi, L.5
Rambaldi, P.6
-
248
-
-
84929501484
-
Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity
-
PID: 25875370
-
Chen J, Li S, Sun W, Li J. Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity. PLoS One. 2015;10(4):e0123864.
-
(2015)
PLoS One
, vol.10
, Issue.4
-
-
Chen, J.1
Li, S.2
Sun, W.3
Li, J.4
-
249
-
-
84963612238
-
PPARgamma agonist pioglitazone improves cerebellar dysfunction at pre-Abeta deposition stage in APPswe/PS1dE9 Alzheimer’s disease model mice
-
COI: 1:CAS:528:DC%2BC28XmtVakt7w%3D, PID: 27059136
-
Toba J, Nikkuni M, Ishizeki M, Yoshii A, Watamura N, Inoue T, et al. PPARgamma agonist pioglitazone improves cerebellar dysfunction at pre-Abeta deposition stage in APPswe/PS1dE9 Alzheimer’s disease model mice. Biochem Biophys Res Commun. 2016;473(4):1039–44.
-
(2016)
Biochem Biophys Res Commun.
, vol.473
, Issue.4
, pp. 1039-1044
-
-
Toba, J.1
Nikkuni, M.2
Ishizeki, M.3
Yoshii, A.4
Watamura, N.5
Inoue, T.6
-
250
-
-
84954359929
-
Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC28XjvFKgsg%3D%3D, PID: 26724934
-
Zou C, Shi Y, Ohli J, Schuller U, Dorostkar MM, Herms J. Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer’s disease. Acta Neuropathol. 2016;131(2):235–46.
-
(2016)
Acta Neuropathol
, vol.131
, Issue.2
, pp. 235-246
-
-
Zou, C.1
Shi, Y.2
Ohli, J.3
Schuller, U.4
Dorostkar, M.M.5
Herms, J.6
-
251
-
-
84891789152
-
New applications of disease genetics and pharmacogenetics to drug development
-
COI: 1:CAS:528:DC%2BC2cXivF2mtrg%3D, PID: 24565016
-
Roses AD, Saunders AM, Lutz MW, Zhang N, Hariri AR, Asin KE, et al. New applications of disease genetics and pharmacogenetics to drug development. Curr Opin Pharmacol. 2014;14:81–9.
-
(2014)
Curr Opin Pharmacol
, vol.14
, pp. 81-89
-
-
Roses, A.D.1
Saunders, A.M.2
Lutz, M.W.3
Zhang, N.4
Hariri, A.R.5
Asin, K.E.6
-
252
-
-
84923238696
-
Effects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain
-
PID: 25671601
-
Crenshaw DG, Asin K, Gottschalk WK, Liang Z, Zhang N, Roses AD. Effects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain. PLoS One. 2015;10(2):e0117973.
-
(2015)
PLoS One
, vol.10
, Issue.2
-
-
Crenshaw, D.G.1
Asin, K.2
Gottschalk, W.K.3
Liang, Z.4
Zhang, N.5
Roses, A.D.6
-
253
-
-
33847169097
-
Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo
-
COI: 1:CAS:528:DC%2BD2sXis1WgtLY%3D, PID: 17167170
-
Iwashita A, Muramatsu Y, Yamazaki T, Muramoto M, Kita Y, Yamazaki S, et al. Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo. J Pharmacol Exp Ther. 2007;320(3):1087–96.
-
(2007)
J Pharmacol Exp Ther
, vol.320
, Issue.3
, pp. 1087-1096
-
-
Iwashita, A.1
Muramatsu, Y.2
Yamazaki, T.3
Muramoto, M.4
Kita, Y.5
Yamazaki, S.6
-
254
-
-
84897459180
-
Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) protects against ceramide-induced cellular toxicity in rat brain astrocytes and neurons by activation of ceramide kinase
-
COI: 1:CAS:528:DC%2BC2cXntFGntbg%3D, PID: 24513118
-
Aleshin S, Reiser G. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) protects against ceramide-induced cellular toxicity in rat brain astrocytes and neurons by activation of ceramide kinase. Mol Cell Neurosci. 2014;59:127–34.
-
(2014)
Mol Cell Neurosci
, vol.59
, pp. 127-134
-
-
Aleshin, S.1
Reiser, G.2
-
255
-
-
67650792427
-
Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels
-
COI: 1:CAS:528:DC%2BD1MXptlegsrk%3D, PID: 19483106
-
Aleshin S, Grabeklis S, Hanck T, Sergeeva M, Reiser G. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels. Mol Pharmacol. 2009;76(2):414–24.
-
(2009)
Mol Pharmacol
, vol.76
, Issue.2
, pp. 414-424
-
-
Aleshin, S.1
Grabeklis, S.2
Hanck, T.3
Sergeeva, M.4
Reiser, G.5
-
256
-
-
84867574313
-
PPARdelta agonist GW501516 prevents uncoupling of endothelial nitric oxide synthase in cerebral microvessels of hph-1 mice
-
Santhanam AV, d’Uscio LV, He T, Katusic ZS. PPARdelta agonist GW501516 prevents uncoupling of endothelial nitric oxide synthase in cerebral microvessels of hph-1 mice. Brain Res. 2012;5(1483):89–95.
-
(2012)
Brain Res
, vol.5
, Issue.1483
, pp. 89-95
-
-
Santhanam, A.V.1
d’Uscio, L.V.2
He, T.3
Katusic, Z.S.4
-
257
-
-
79952189004
-
Vascular PPARdelta protects against stroke-induced brain injury
-
COI: 1:CAS:528:DC%2BC3MXitVOgur0%3D, PID: 21205987
-
Yin KJ, Deng Z, Hamblin M, Zhang J, Chen YE. Vascular PPARdelta protects against stroke-induced brain injury. Arterioscler Thromb Vasc Biol. 2011;31(3):574–81.
-
(2011)
Arterioscler Thromb Vasc Biol
, vol.31
, Issue.3
, pp. 574-581
-
-
Yin, K.J.1
Deng, Z.2
Hamblin, M.3
Zhang, J.4
Chen, Y.E.5
-
258
-
-
0035108316
-
PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture
-
COI: 1:STN:280:DC%2BD3M3lvFOhtQ%3D%3D, PID: 11241737
-
Saluja I, Granneman JG, Skoff RP. PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia. 2001;33(3):191–204.
-
(2001)
Glia.
, vol.33
, Issue.3
, pp. 191-204
-
-
Saluja, I.1
Granneman, J.G.2
Skoff, R.P.3
-
259
-
-
84865191020
-
Neuron-specific deletion of peroxisome proliferator-activated receptor delta (PPARdelta) in mice leads to increased susceptibility to diet-induced obesity
-
COI: 1:CAS:528:DC%2BC38Xht1Gnsr%2FE, PID: 22916190
-
Kocalis HE, Turney MK, Printz RL, Laryea GN, Muglia LJ, Davies SS, et al. Neuron-specific deletion of peroxisome proliferator-activated receptor delta (PPARdelta) in mice leads to increased susceptibility to diet-induced obesity. PLoS One. 2012;7(8):e42981.
-
(2012)
PLoS One
, vol.7
, Issue.8
-
-
Kocalis, H.E.1
Turney, M.K.2
Printz, R.L.3
Laryea, G.N.4
Muglia, L.J.5
Davies, S.S.6
-
260
-
-
84955319231
-
Regulation of the orexigenic neuropeptide, enkephalin, by PPARdelta and fatty acids in neurons of the hypothalamus and forebrain
-
COI: 1:CAS:528:DC%2BC2MXhsFKqu7zE, PID: 26332891
-
Poon K, Alam M, Karatayev O, Barson JR, Leibowitz SF. Regulation of the orexigenic neuropeptide, enkephalin, by PPARdelta and fatty acids in neurons of the hypothalamus and forebrain. J Neurochem. 2015;135(5):918–31.
-
(2015)
J Neurochem
, vol.135
, Issue.5
, pp. 918-931
-
-
Poon, K.1
Alam, M.2
Karatayev, O.3
Barson, J.R.4
Leibowitz, S.F.5
-
261
-
-
84899735022
-
Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) in the brain
-
COI: 1:CAS:528:DC%2BC2cXntlGnurg%3D, PID: 24644281
-
Yu S, Levi L, Casadesus G, Kunos G, Noy N. Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) in the brain. J Biol Chem. 2014;289(18):12748–58.
-
(2014)
J Biol Chem
, vol.289
, Issue.18
, pp. 12748-12758
-
-
Yu, S.1
Levi, L.2
Casadesus, G.3
Kunos, G.4
Noy, N.5
-
262
-
-
84930935754
-
The effect of neuronal conditional knock-out of peroxisome proliferator-activated receptors in the MPTP mouse model of Parkinson’s disease
-
Mounsey RB, Martin HL, Nelson MC, Evans RM, Teismann P. The effect of neuronal conditional knock-out of peroxisome proliferator-activated receptors in the MPTP mouse model of Parkinson’s disease. Neuroscience. 2015;6(300):576–84.
-
(2015)
Neuroscience
, vol.6
, Issue.300
, pp. 576-584
-
-
Mounsey, R.B.1
Martin, H.L.2
Nelson, M.C.3
Evans, R.M.4
Teismann, P.5
-
263
-
-
85008437496
-
-
Delmedico MK, Severynse-Stevens D, Oliver WR. DB959 is a novel, dual PPAR δ/γ agonist which controls glucose and regulates triglycerides and HDLc in animal models of T2D and dyslipidemia. In: 69th Annual Scientific Sessions of the American Diabetes Association; 2009. p. 365-OR
-
Delmedico MK, Severynse-Stevens D, Oliver WR. DB959 is a novel, dual PPAR δ/γ agonist which controls glucose and regulates triglycerides and HDLc in animal models of T2D and dyslipidemia. In: 69th Annual Scientific Sessions of the American Diabetes Association; 2009. p. 365-OR.
-
-
-
-
265
-
-
84999075071
-
T3D-959: a multi-faceted disease remedial drug candidate for the treatment of Alzheimer’s disease
-
Didsbury J, de la Monte SM. T3D-959: a multi-faceted disease remedial drug candidate for the treatment of Alzheimer’s disease. Alzheimer Dement. 2015;11(7):906.
-
(2015)
Alzheimer Dement.
, vol.11
, Issue.7
, pp. 906
-
-
Didsbury, J.1
de la Monte, S.M.2
-
266
-
-
84960111185
-
T3D-959: a multi-faceted disease remedial drug candidate for the treatment of Alzheimer’s disease
-
COI: 1:CAS:528:DC%2BC28XksFCgs7o%3D, PID: 26836193
-
Tong M, Deochand C, Didsbury J, de la Monte SM. T3D-959: a multi-faceted disease remedial drug candidate for the treatment of Alzheimer’s disease. J Alzheimers Dis. 2016;51(1):123–38.
-
(2016)
J Alzheimers Dis
, vol.51
, Issue.1
, pp. 123-138
-
-
Tong, M.1
Deochand, C.2
Didsbury, J.3
de la Monte, S.M.4
|